

The diverse roles of integrin $\alpha 3\beta 1$ in cancer: Lessons learned from skin and breast carcinogenesis

Ramovš, V.

Citation

Ramovš, V. (2021, February 18). The diverse roles of integrin $\alpha 3\beta 1$ in cancer: Lessons learned from skin and breast carcinogenesis. Retrieved from https://hdl.handle.net/1887/3135050

Version: Publisher's Version

License: License agreement concerning inclusion of doctoral thesis in the

Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/3135050

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle http://hdl.handle.net/1887/3135050 holds various files of this Leiden University dissertation.

Author: Ramovš, V.

Title: The diverse roles of integrin $\alpha 3\beta 1$ in cancer: Lessons learned from skin and breast

carcinogenesis

Issue date: 2021-02-18



THE OPPOSING ROLES OF LAMININ-BINDING INTEGRINS IN CANCER

Published in Matrix Biology, Volumes 57-58, pages 213-243 (2017)

Veronika Ramovs*, Lisa te Molder*, Arnoud Sonnenberg

Division of Cell biology, The Netherlands Cancer Institute, Amsterdam, The Netherland *authors contributed equally to this work

Correspondence to Arnoud Sonnenberg: a.sonnenberg@nki.nl

ABSTRACT

Integrins play an important role in cell adhesion by linking the cytoskeleton of cells to components in the extracellular matrix. In this capacity, integrins cooperate with different cell surface receptors, including growth factor receptors and G-protein coupled receptors, to regulate intracellular signaling pathways that control cell polarization, spreading, migration, survival, and gene expression. A distinct subfamily of molecules in the integrin family of adhesion receptors is formed by receptors that mediate cell adhesion to laminins, major components of the basement membrane that lie under clusters of cells or surround them, separating them from other cells and/or adjacent connective tissue. During the past decades, many studies have provided evidence for a role of laminin-binding integrins in tumorigenesis, and both tumor-promoting and suppressive activities have been identified. In this review we discuss the dual role of the laminin-binding integrins $\alpha 3\beta 1$ and $\alpha 6\beta 4$ in tumor development and progression, and examine the factors and mechanisms involved in these opposing effects.

LAMININ-BINDING INTEGRINS, WHAT THEY ARE AND WHAT THEY DO

Laminins are large heterotrimeric extracellular matrix (ECM) glycoproteins that contain an α , a β , and a y chain. They are major components of the basement membrane (BM) that separates the nervous system, epithelial, endothelial, fat and muscle cells from adjacent connective tissue [1]. The BM, however, is not just a physical barrier; it also contributes to the adhesion, proliferation, migration and survival of cells. Integrins are heterodimeric transmembrane glycoproteins that function as adhesion receptors for ligands in the extracellular matrix (ECM) and transduce mechanical signals from the ECM into biochemical signals within the cell. Four integrins recognize laminins as their extracellular ligands: α3β1, α6β1, α7β1 and α6β4 (reviewed in [2]). Their specificity and affinity for binding to various laminin isoforms differ considerably [3–5] (Table 1). Alternative mRNAs splicing of the α 3, α 6 and α 7 subunits further increases the functional diversity of these laminin-binding integrins by generating evolutionary conserved isoforms with different affinities for ligand binding and signaling activities [6]. The α6 and α7 subunits have distinct isoforms that differ in both their extracellular (X1 and X2) and cytoplasmic domains (A and B), while the α3 subunit only exists as two distinct cytoplasmic variants [7–14]. The expression of these isoforms is tissue specific and developmentally regulated [15–18], however a full understanding of their role is still lacking.

Integrin $\alpha6\beta4$ is expressed at the base of most epithelial cells, but also by a subset of endothelial cells [19] and by perineural fibroblasts and Schwann cells in peripheral nerves [20,21]. It mediates cell adhesion to laminins and plays a crucial role in the formation of specific cell-matrix complexes, *i.e.* hemidesmosomes (HDs) [22]. Hemidesmosomal dysfunction is associated with a group of inherited disorders called epidermolysis bullosa, symptoms of which are severe blistering of the skin and mucosal membranes [23]. Mice lacking either the integrin $\alpha6$ or $\beta4$ subunit display very similar defects in skin and mucosal membranes, and die perinatally [24–26].

Despite sharing the common $\beta1$ subunit, the integrins $\alpha3\beta1$, $\alpha7\beta1$ and $\alpha6\beta1$ have unique functions and distinct distribution patterns. Integrin $\alpha3\beta1$ is most abundant in skin, kidneys, lungs, intestine, bladder and stomach. In these tissues, it mediates adhesion of epithelial cells to laminin-332 and -511 in the BM, and plays a role in the maintenance of cell-cell contacts. Recently, mutations in the gene encoding the $\alpha3$ subunit (*ITGA3*) have been identified in patients suffering from a congenital nephrotic syndrome, interstitial lung disease and a mild form of epidermolysis bullosa [27–29]. Similar symptoms have been previously described in genetically engineered mice lacking $\alpha3\beta1$ [30]. Notably, the skin defects observed in the absence of $\alpha3\beta1$ occur

early in life and are associated with micro-blisters and a disorganized BM. Later in life, these defects are no longer observed [31,32].

LAMININ ISOFORM SPECIFICITY		GENE	MOUSE PHENOTYPE		HUMAN DISEASE	
-332 -511/521	α6β1 α6β 4	Itgb4	LETHAL, Perinatal	Severe skin blistering	Epidermolysis bullosa	
-111, -332, -511/521		Itga6	LETHAL Birth	Severe skin blistering, defects in cerebral cortex and retina	Epidermolysis bullosa	
-211/221, -411 -511/521, -332 -211/221	α3β1 α	Itgb1	LETHAL E 5.5	Inner cell mass deterioration	Lethal	
		Itga3	LETHAL Birth	Defects in kidneys, lungs, skin, and cerebral cortex. Disorganization of the BM	Congenital nephrotic syndrome, interstitial lung disease, and epidermolysis bullosa	
-211/221 -111, -511/521	α7β1	Itga7	VIABLE Fertile	Muscular dystrophy	Congenital myopathy	

Table 1: The ligand-binding specificity of the laminin-binding integrins (bold printed – laminin isoforms reported to bind with the highest affinity) and reported phenotypes of mice and human diseases linked to non-functional integrins

Integrin $\alpha7\beta1$ is most prominently expressed in cardiac and skeletal muscles, where it connects muscle fibers to laminin-211/221 in the BM of the myotendinous junction. In line with its function, patients with a loss-of-function mutation in the gene encoding the $\alpha7$ subunit (*ITGA7*) suffer from congenital myopathy [33], and mice lacking $\alpha7\beta1$ develop muscular dystrophy [34].

Finally, integrin $\alpha6\beta1$ is predominantly expressed on platelets, leukocytes, gametes and some epithelia. It binds to a wide range of laminin isoforms, with the highest affinity to laminin-111, -511 and -332 [5]. Apart from a defect in laminar organization of the developing cerebral cortex and retina, seen in the $\alpha6$ -deficient mice (but not in $\beta4$ -deficient mice), no other defects are associated with the absence of this integrin α subunit in mice [26,35]. The $\beta1$ subunit is ubiquitously expressed and can bind to as many as 12 different α subunits (reviewed in [2]). Therefore, it is not surprising that its depletion causes a failure of embryonic development [36].

Laminin-binding integrins can be found in two different adhesion complexes, focal adhesions (FAs) and HDs. FAs are dynamic protein complexes that form mechanical links between the ECM and the actomyosin cytoskeleton [37]. The dynamic regulation of FAs and the reorganization of the associated actin cytoskeleton are important determinants for cell migration. HDs are more stable adhesion structures that act as

anchoring sites for intermediate filaments (reviewed in [38–41]). These adhesions need to be disassembled during migration and several mechanisms have been suggested to contribute to the disassembly of HDs, including endocytosis of HD proteins [42,43], laminin chain processing [44], cleavage of the $\beta 4$ subunit by calpain or caspases [45,46], and phosphorylation of HD proteins [47–52]. Upon dissociation of HDs, $\alpha 6\beta 4$ has been reported to be redistributed to actin-rich filopodia and lamellae [53,54], where it plays a role in the regulation of cell migration. However, the mechanism responsible is poorly understood.

In addition to their role in maintaining structural integrity of tissues, the laminin-binding B1 integrins also function as bidirectional signaling molecules. "Inside-out" signaling regulates the binding affinity and/or avidity of the integrin to its ECM ligand, while "outside-in" signaling is triggered upon adhesion and results in the transduction of signals into the cell (reviewed in [55–58]). As integrins lack intrinsic enzymatic activity, they signal through direct or indirect interactions of their cytoplasmic domains with numerous intracellular effector molecules (reviewed in [59-61]). Classical integrin outside-in signaling triggers autophosphorylation of focal adhesion kinase (FAK) [62]. Consequently, the FAK/Src complex is activated, resulting in the stimulation of multiple downstream signaling pathways, leading to the activation of effectors such as mitogen-activated protein kinases (MAPKs) ERK1/2 and JNK, as well as the Rho-family of small GTPases Cdc42 and Rac1. Through these effector molecules, the lamininbinding \(\beta \) integrins regulate cell polarization, spreading, migration, survival, and gene expression of cells [59]. Interestingly, compared to the B1 integrins that bind to fibronectin, the laminin-binding integrins support strong activation of Rac1 and Cdc42, and a minimal activation of RhoA. It has recently been pointed out by Stipp in his expert review [63] that this particular signaling results in the formation of smaller focal contacts on a laminin matrix as well as in dynamic actin cytoskeleton remodeling and rapid cell migration. Although $\alpha6\beta4$ is reported to be involved in the activation of many of the kinases mentioned above, α6β4 and β1-integrins use different signaling mechanisms and the current understanding is that $\alpha6\beta4$ needs to be dissociated from HDs to fulfill its role in signaling [64]. Whether $\alpha6\beta4$ needs to adhere to laminin-332 in order to signal is unclear, since both adhesion-dependent and adhesion-independent signaling have been reported [65–68]. Data suggests that in transformed cells the β4 cytoplasmic domain is phosphorylated on specific tyrosine residues that serve as a docking platform for various signaling molecules to amplify the signaling output of growth factor receptors [69-71].

Integrin-mediated signaling can be additionally enhanced or modulated through interaction of integrins with integrin-associated proteins (IAPs), e.g. tetraspanins [72],

urokinase-type plasminogen activator receptor (uPAR) [73] and several growth factor receptors [74]. Therefore, extensive crosstalk takes place between pathways activated by integrins and other receptors, especially receptor tyrosine kinases (RTKs).

LAMININ-BINDING INTEGRINS AND CANCER

Over the last decades evidence for a role of laminins in cancer has accumulated and been addressed in several excellent reviews [75-77]. Laminin-332, -511 and -111 are reported to be particularly important in carcinogenesis and the motility of tumor cells [77]. Accordingly, $\alpha 3\beta 1$, $\alpha 6\beta 1$ and $\alpha 6\beta 4$ have all been implicated in the development and progression of cancer, but there is little evidence for such role of $\alpha 781$ in tumorigenesis and cancer progression [78–81]. In the limited amount of available literature its tumor suppressing function in a variety of tumor cell types, as well as in a reduction of metastatic potential in melanoma cells, is described (reviewed in [63]). Recently it was reported that $\alpha 7\beta 1$ is upregulated in biopsies of hepatocellular carcinoma, while *in vitro* its downregulation caused decreased invasion and migration, indicating that $\alpha 7\beta 1$ can also act as a tumor promoter [82]. Such dual role in cancer is not restricted to α7β1; α 6 β 4 and especially α 3 β 1 can have both, disease suppressive and promoting roles. This does not seem to be the case for $\alpha6\beta1$, which has been predominantly characterized as a tumor promoter, contributing to the spreading and invasion of tumors as well as mediating dissemination and the formation of metastases in areas rich in laminin, such as bone matrix and the space surrounding the nerve of the prostate gland. The role of α6β1 in cancer progression has been recently reviewed by others [63,83].

In this review we will focus on laminin-binding integrins with both an inhibitory and a promoting role in cancer, i.e. $\alpha 3\beta 1$ and $\alpha 6\beta 4$, and try to elucidate the factors and mechanisms involved in these opposing effects. Cancer is a disease with several different stages of development, which can be correlated to specific processes that are essential for its progress and development, i.e. hallmarks of cancer [84]. During primary tumorigenesis cancer cells exhibit sustained proliferation and avoidance of apoptosis. With growing tumor mass, a switch of metabolism and angiogenesis become important for the further development of the disease. During later stages of tumor progression, cancer cells acquire invasive properties in order to spread to distant tissues and form metastases. Integrins represent an important link between tumors and their environment as well as between different tumor cells within the tumor mass. Their role in each stage of tumorigenesis therefore will depend on external influences, for example, the molecular composition of the microenvironment and juxtacrine signaling from neighboring cells. Also oncogenic insults can have an effect on the function of integrins in different stages of cancer progression.

INETGRIN α3β1 AND CANCER

The opposing role of laminin-binding integrins in cancer is especially evident when considering $\alpha 3\beta 1$ -mediated tumorigenesis events (**Table 2**). From a number of studies it is clear that different stages of cancer can be influenced by the presence or absence of $\alpha 3\beta 1$ and, conversely, that transformed cells can modulate the function of $\alpha 3\beta 1$ by regulating its expression or post-translational modifications, through IAPs and via the induction of $\alpha 3\beta 1$ -mediated signaling. Furthermore, the expression of $\alpha 3\beta 1$ in transformed cells can be influenced by oncogenic stimuli, such as the activation of K-Ras, and, vice versa, $\alpha 3\beta 1$ can regulate the expression of a large number of genes in immortalized keratinocytes [85,86]. This suggests that transformed cells can be dependent on $\alpha 3\beta 1$ for sustaining signaling pathways and cellular processes.

TISSUE		JLATED/ ROMOTER	DOWNREGULATED/ CANCER SUPRESSOR	
	PRIMARY	METASTASIS/	PRIMARY	METASTASIS/
	TUMORS	INVASION	TUMORS	INVASION
SKIN	[87-89]	[87]	[90]	[89]
BRAIN	[91,92]	[93,94]		[95]
ORAL CAVITY	[96]	[97–101]	[102]	[103]
HEAD AND NECK	[104]	[105]		
LUNG	[106,107]	[108,109]	[90,110]	[111]
BREAST	[112–118]	[117,119]	[118]	[118,120-122]
REPRODUCTIVE SYSTEM	[123]			[124–130]
STOMACH AND INTESTINE	[131]	[132–134]		[135,136]
PANCREAS	[137]			
LIVER	[138]	[138]		
BLADDER AND KIDNEYS	[139,140]			[141]
BONE			[142]	

Table 2: Summary of the studies on the role of $\alpha 3\beta 1$ in cancer, including either biopsies of human diseased tissue or *in vivo* mammalian models. A role of $\alpha 3\beta 1$ in both promoting and suppressing tumorigenesis and metastasis has been described.

Role of $\alpha 3\beta 1$ in supporting sustained proliferation and avoidance of apoptosis

One of the most fundamental traits of cancer is the ability of tumor cells to maintain sustained proliferation. Integrins regulate cell proliferation through adhesion to the ECM [143]. Although the adhesion-dependent control of cell proliferation is generally downregulated in tumors, several studies have shown that proliferation of transformed cells can still be affected by integrin-mediated adhesion. Two recent studies, investigating the role of $\alpha 3\beta 1$ in tumorigenesis of the epithelium of the skin and

mammary gland, showed that $\alpha 3\beta 1$ is essential for the initiation of tumors and efficient proliferation of tumor cells [89,116]. The impaired proliferation in mammary epithelia was associated with the downregulation of activated FAK, resulting in a reduction of active Rac1 and its effector serine/threonine-protein kinase PAK1, and therefore in reduced activation of ERK1/2 and JNK [116]. This is consistent with the results of an earlier study, showing that the engagement of laminin-332 by $\alpha 3\beta 1$ is essential for growth factor-stimulated cell proliferation, mediated through activation of the MAPK signaling pathway [144]. Both studies mentioned above observed that transformed cells deposit laminin into the matrix; therefore, their proliferation may still be dependent on signals, derived from integrin-mediated cell adhesion. In line with this, both $\alpha 3\beta 1$ and laminin are required for an efficient proliferation of various types of tumors and the upregulation of laminin-511 together with $\alpha 3\beta 1$ was shown to be a marker of poor prognosis in breast cancer [117,145,146].

It is therefore evident that $\alpha3\beta1$ can promote proliferation of tumors that are adherent to the pre-existing or newly deposited laminin matrix. However, in later stages of carcinogenesis, when tumors rely less on adherent-mediated proliferation, loss of $\alpha3\beta1$ may destabilize E-cadherin-mediated cell-cell adhesion, resulting in epithelial to mesenchymal transition (EMT)-like events and consequently increased tumor progression and metastatic growth at distant sites [128,147]. Loss of $\alpha3\beta1$ can also contribute to metastatic growth through interactions of tumors with the metastatic environment. It was shown that *in vitro* the adhesion and proliferation of $\alpha3$ -deficient prostate carcinoma cells on laminin-332 was impaired, but the growth of the tumor was increased when injected into mice. Increased growth of $\alpha3$ -depleted tumor cells was also observed *in vitro* when these cells were co- cultured with stromal cells or grown in fibroblast-conditioned medium [129]. These observations further suggest that the role of $\alpha3\beta1$ in modulating cancer cell proliferation is dual, depending on the stage of tumor progression (**Fig. 1**).

Integrins also contribute to tumorigenesis by regulating cell survival; ligated integrins can prevent pro- apoptotic signaling cascades initiated by anoikis (cell death by loss of adhesion) and relay survival signals. Studies of transformed cells depleted of $\alpha 3\beta 1$ showed increased activation of caspase-3/7, reduced cell survival and increased radiosensitivity [116,148,149]. In all cases, $\alpha 3\beta 1$ supported survival through adhesion to laminin and initiation of the FAK/ERK signaling pathway, indicating the importance of this mechanism.

Role of α3β1 in tumor-associated angiogenesis

The potential role of $\alpha 3\beta 1$ in regulating angiogenesis has received relatively little attention and is not yet fully understood. In Itga3 knockout mice the capillary loops in the kidneys are dilated and their number is reduced [30]. Furthermore, conditional deletion of Itga3 in the epidermis of mice caused impaired cutaneous wound healing, due to a defect in angiogenesis and failure of α3-negative keratinocytes to promote the expression of the pro-angiogenic factor MRP3 (mitogen-regulated protein 3) [150]. In cancer-induced angiogenesis, α3β1 seems to act as both a promoter and suppressor of angiogenesis, and it influences vascular formation when expressed by tumor or endothelial cells (Fig. 1). Studies investigating the effect of $\alpha 3\beta 1$ on endothelial cells mostly reported its suppressive function in angiogenesis, due to the inhibition of cyclooxygenase-2 (COX-2)-dependent angiogenic signaling, the regulation of vascular endothelial growth factor (VEGF), or the inhibition of endothelial cell proliferation, migration, and tubule formation [90,110,151,152]. In contrast, when expressed on tumor cells, $\alpha 3\beta 1$ is predominantly associated with the promotion of angiogenesis. The expression of COX-2 and $\alpha 3\beta 1$ is positively correlated in invasive ductal carcinoma, resulting in higher blood vessel density [115]. In MDA-MB-231 breast cancer cells, α3β1 controls the expression of COX-2 and influences endothelial cell function and invasion of tumor cells [112]. A possible explanation for the role of $\alpha 3\beta 1$ in COX-2-mediated angiogenesis and stimulation of the tumor's microenvironment was recently provided by Subbram et al. [153], who showed that α3β1 can directly influence COX-2 expression by stabilizing its mRNA. Furthermore, there is data suggesting that the association of $\alpha 3\beta 1$ with non-conventional ligands, such as the noncollagenous domain of the $\alpha 3$ chain of type IV collagen [α3(IV)NC1] [110], a tissue inhibitor of metalloproteinases (TIMP-2) [151,152,154] and thrombospondin-1 (TSP-1) [155,156], has an impact on tumorassociated angiogenesis.

Integrin $\alpha 3\beta 1$ -dependent regulation of angiogenesis can be also mediated via its lateral association with tetraspanin CD151, an established IAP (see below). An increased expression of CD151 is correlated with increased vascularity in breast cancer, and *in vitro* experiments in three-dimensional (3D) extracellular matrices showed that CD151 modulates the response of endothelial cells to cancer cells through its association with both $\alpha 3\beta 1$ and $\alpha 6\beta 4$ [157].

Role of $\alpha 3\beta 1$ in invasion and metastasis

The literature describing the role of $\alpha 3\beta 1$ in later stages of tumor progression pays almost equal amount of attention to its cancer promoting and suppressing functions. While in numerous clinical studies a positive correlation between $\alpha 3\beta 1$ expression and tumor invasiveness or poor prognosis has been observed, opposite findings have also

been reported (**Table 2**). A similar trend was observed in *in vitro* studies investigating the invasive and migratory phenotype of cells from transformed cell lines. While an increased expression of $\alpha 3\beta 1$ in a head and neck carcinoma cell line is correlated with a more invasive phenotype [105], a low expression of $\alpha 3\beta 1$ has been associated with reduced migration and invasiveness of many different types of tumor cells [158–160]. On the contrary, loss or inhibition of $\alpha 3\beta 1$ function can result in enhanced migration and invasion of tumor cells [89,124,135,161].




Figure 1: The role of α3β1 in tumor cell proliferation and angiogenesis. Ligation of α 3β1 by laminins can result in the initiation of survival and growth signals via activation of FAK signaling, leading to the activation of the MAPK signaling pathway, which can additionally be supported through crosstalk with GFRs or upon association of α 3β1 with the tetraspanin CD151. In later stages of tumor progression, when tumor cells rely less on adherent-mediated survival signaling, loss of α 3β1 can destabilize adherent junctions, promote EMT and proliferation. Loss of α 3β1 can promote metastatic growth also through interaction of tumor cells with other cells (e.g. fibroblasts) in a metastatic environment. When expressed on tumor cells, α 3β1 can promote angiogenesis through stabilization of COX2 and via its lateral association with CD151. However, when present on endothelial cells, α 3β1 downregulates proliferation and tubule formation and inhibits angiogenesis via inhibition of COX2-mediated signaling and regulation of VEGF signaling. GFR, growth factor receptor; EMT, epithelial to mesenchymal transition.

Different transcription factors have been reported that can either positively or negatively regulate the expression of $\alpha 3\beta 1$ in tumor cells in order to acquire a more aggressive phenotype [142,162]. This suggests that the presence of $\alpha 3\beta 1$ can have either beneficial or unfavorable effect on tumor cell invasion, and that it is important enough for tumor cells to develop mechanisms for regulating its expression. A remaining question is: what determines whether tumor cells will require either the presence or absence of $\alpha 3\beta 1$ for successful invasion and the formation of metastases?

Laminin-dependent ligation of $\alpha 3\beta 1$

Ligation of $\alpha 3\beta 1$ by laminin-511 or -332 is one of the major events through which this integrin mediates cell adhesion and migration. This makes laminins of key importance for $\alpha 3\beta 1$ -mediated effects on cancer progression and invasion. Even more so since, as already discussed, laminins are implicated in the progression and spreading of cancer. In an early study it was shown that $\alpha 3\beta 1$ is essential for the migration of keratinocytes on laminin-332 during wound healing [163]. A decade later Choma *et al.* [164] demonstrated that persistent keratinocyte migration is driven via the interaction of $\alpha 3\beta 1$ with laminin-332, which induces FAK/Src kinase activity, thereby promoting Rac1 activation and polarized lamellipodium extension.

There is a strong positive correlation between the degree of invasiveness of glioma cells and $\alpha 3\beta 1$ -mediated migration. As it has been pointed out in a recent review, the attachment of the glioma cells to the ECM must be transient for them to be able to invade [165]. Furthermore, ECM rich in laminin-332 and -511 contributes strongly to the migration of highly invasive gliomas [93,166,167], while downregulation of $\alpha 3\beta 1$ in glioma cells led to decreased migration and invasiveness [93], which was correlated with decreased phosphorylation of ERK1/2 [94]. In invasive protrusions of glioblastomas, $\alpha 3\beta 1$ was found to be co-localized with the Ephrin A2 (EphA2), a known promoter of cancer invasiveness, making it plausible that the cross-talk between EphA2 and $\alpha 3\beta 1$ additionally contributes to the adhesion-dependent signaling that leads to a more invasive phenotype [168,169]. Integrin $\alpha 3\beta 1$ -mediated cell adhesion in areas of the brain that are rich in laminin not only drives the invasion of glioma cells, but also plays a role in the formation of brain metastases of non-small cell lung carcinoma [108].

A pattern is now emerging of how laminin-332 and -511 promote the spreading of cancer cells via $\alpha 3\beta 1$. Firstly, they facilitate $\alpha 3\beta 1$ -mediated tumor cell migration and invasion from the primary tumor site, which, in addition to the cases mentioned above, was observed in numerous other types of cancers [79,170–176]. Secondly, ligation of $\alpha 3\beta 1$ by laminin-332 can increase the secretion of matrix metalloproteinase-9 (MMP-9), which then further promotes the invasion and migration through the dense ECM

[119,173,177]. Thirdly, laminins deposited by endothelial cells, can mediate $\alpha 3\beta 1$ -driven migration of tumor cells and stimulate trans-endothelial tumor cell invasion, thereby promoting tumor cell dissemination through the vasculature [178,179]. Fourthly, $\alpha 3\beta 1$ expressed by endothelial cells may strengthen the adhesion of circulating tumor cells to the endothelium by stabilizing the binding of endothelium-expressed galectin-3 and cancer-associated carbohydrate Thomsen-Friedenreich antigen (TF-Ag) [180]. Lastly, $\alpha 3\beta 1$ can mediate the initiation of new metastases in laminin-rich environment. Several studies have established a role of $\alpha 3\beta 1$ in haptotatic migration and invasion toward laminin-511, suggesting that $\alpha 3\beta 1$ plays an active role in the colonization of laminin-rich tissues by tumor cells [119,181–183]. This was confirmed in *in vivo* mouse studies, observing that $\alpha 3\beta 1$ drives the formation of metastasis to the lung, lymph nodes and peritoneum [109,117,133,177,184].

Ligation of α3β1 by laminin, however, does not always clearly promote the spreading and invasion of cancer cells. For example, in highly invasive and metastatic prostate carcinoma cells the expression of α3β1 was decreased and they failed to spread when grown in vitro [124]. Furthermore, a recent study of patient samples of squamous cell carcinomas of the lower lip showed the absence of α3β1 at the invasive front, where the expression of laminin-332 was often detected [102]. One possible explanation for the anti-invasive-effect of ligated $\alpha 3\beta 1$ is that the integrin suppresses the formation of invadopodia, actin-linked structures with putative adhesion properties, which are frequently observed to mediate BM degradation in epithelial tumors. It was proposed that a balance of focal contacts and invadopodia is necessary for cells to migrate and invade the BM [185]. In fact, Liu et al. [186] recently showed that depletion of either laminin-332 or α3β1 resulted in an increased number of invadopodia in bladder carcinoma cells. They proposed a mechanism, by which laminin-332-α3β1 interaction acts as a potent upstream inhibitor of cell invasion via mediating focal contacts that in turn limit the availability of active Src, necessary for inducing the formation of invadopodia.

Association of $\alpha 3\beta 1$ with tetraspanins

The ability of $\alpha 3\beta 1$ to interact with several IAPs offers further explanation for its dual role in cancer invasion and its progression in general. Tetraspanins, multispanning membrane proteins that cluster into tetraspanin-enriched microdomains (TEMs) on the plasma membrane, are one of the most prominent proteins that can interact with laminin-binding integrins, thereby influencing their localization and function [63,72]. Several tetraspanins, including CD9, CD81 and CD63 have been suggested to associate with $\alpha 3\beta 1$ and to influence the migration and invasiveness of tumor cells. With a few exceptions, these complexes are mainly associated with reduced migration and low

metastatic potential, and thus a better prognosis [98,126,135,187–189]. Recently, the tetraspanin CO-029 was found to form a complex with $\alpha 3\beta 1$ and rictor in malignant gliomas, and thus to mediate migration of glioma cells via mammalian target of rapamycin (mTOR) complex 2 (mTORC2), of which rictor is a key component [190]. However, a clear understanding of how these tetraspanins associate with $\alpha 3\beta 1$ and regulate $\alpha 3\beta 1$ -mediated migration and invasiveness is still lacking.

A direct and stable association has only been shown for CD151 and $\alpha3\beta1$ [191,192]. The interaction of CD151 and $\alpha3\beta1$ influences the distribution of $\alpha3\beta1$ and shifts it from FAs into TEMs [193]. Furthermore, it strengthens $\alpha3\beta1$ -mediated cell adhesion and promotes the proliferation and migration of different types of tumors cells on laminin-332 [194–196]. Two major mechanisms may account for the CD151-dependent regulation of tumor cell behavior by $\alpha3\beta1$. Firstly, CD151, which contains a YXX ϕ endocytosis motif in its C-terminal cytoplasmic domain, may stimulate cell migration by facilitating $\alpha3\beta1$ recycling [197]. Secondly, CD151 may contribute to pro-migratory signaling of $\alpha3\beta1$ by suppressing RhoA activity and formation of stress fibers [63,164,198,199]. Additionally, the signaling properties of $\alpha3\beta1$ may be influenced by phosphatidylinositol 4-kinase (PI4K) that is associated with CD151 [192] (**Fig. 2**).

Recent data suggests that CD151 can also control cell migration independently of its association with $\alpha 3\beta 1$, and that the balance between integrin-free CD151 and CD151- $\alpha 3\beta 1$ complexes is important with regard to tumor invasion [130,200,201]. Scales *et al.* [199] demonstrated that the ligation of $\alpha 3\beta 1$ by laminin promoted the association between $\alpha 3\beta 1$ and CD151 and that cells lacking $\alpha 3\beta 1$ exhibited increased formation of CD151 homodimers. This suggests that $\alpha 3\beta 1$ -mediated cell adhesion to laminin skews the balance from CD151-CD151 homodimers towards CD151- $\alpha 3\beta 1$ complexes. The balance can also be altered by changes in the expression of either $\alpha 3\beta 1$ or CD151, which is not uncommon in cancer [63]. Alternatively, association of $\alpha 3\beta 1$ with CD151 could be regulated via $\alpha 3$ or $\beta 1$ glycosylation, as it was shown in highly metastatic melanoma cells [202].

In breast cancer, it was shown that the complex of CD151 and $\alpha3\beta1$ mediates malignancy through interaction with ErbB-2 (HER2) [203,204]. In invasive ductal carcinomas, the CD151- $\alpha3\beta1$ complex is a marker of poor outcome, and experiments with ErbB-2 overexpressing breast cancer cells indicated that CD151- $\alpha3\beta1$ complexes promote dimerization of ErbB-2 by keeping Rho activity low [114]. In contrary to invasive ductal carcinomas, in invasive lobular carcinomas poor patient survival is connected to the lack of correlation between CD151 and $\alpha3\beta1$ [118].




Figure 2: The interaction of integrin $\alpha 3\beta 1$ with CD151 and uPAR can affect tumor cell migration and invasion. Integrin $\alpha 3\beta 1$ can form complexes with several IAPs, which have an impact on the progression and development of tumors. The association of CD151 with $\alpha 3\beta 1$ might be required to prevent the integrin from becoming linked to the actomyosin cytoskeleton and thus from supporting RhoA activity. The suppression of RhoA activity will lead to a shift of the Rho/Rac balance in favor of Rac1 and hence to the formation of smaller focal adhesion complexes and the activation of cytoskeleton remodeling. Additionally, the association of CD151 may promote tumor cell migration and invasion by facilitating the recycling of $\alpha 3\beta 1$. Furthermore, $\alpha 3\beta 1$ -CD151-mediated suppression of RhoA activity and Slug expression may stabilize adherens junctions, thereby inhibiting tumor cell migration, invasion and passive shedding and dissemination of tumor cells. However, it may favor tumor spreading via collective cell migration. The association of $\alpha 3\beta 1$ with CD151 may also skew the balance from CD151 homodimers, which can also have an impact on the migratory and invasive properties of tumor cells. The $\alpha 3\beta 1$ -uPAR complex can promote migration and invasion of tumor cells via activating the Src/ERK signaling pathway and/or upregulating uPA expression.

The biological differences between the two diseases were related to differences in cell-cell and cell-matrix interactions, the loss of E-cadherin being the most prominent characteristic of invasive lobular carcinoma [205]. As previously mentioned, $\alpha 3\beta 1$ does not only mediate adhesion and migration on laminin substrates, but also plays a role in regulating the stability of cell-cell contacts. Although a precise mechanism has not yet been defined, it has been suggested that the CD151- $\alpha 3\beta 1$ complex controls the stability of E-cadherin mediated cell-cell adhesion by regulating the expression of the membrane protein tyrosine phosphatase PTPm and its association with the E-cadherin-catenin complex in embryonic kidney cells [206]. Stipp and colleagues [207,208], however,

showed that this mechanism is not operative in A431 epidermoid carcinoma cells. In these cells, CD151 promotes the stability of cell-cell junctions by reducing $\alpha 3\beta 1$ -dependent activation of RhoA. In the absence of CD151, Rho activation is increased, which resulted in reduced collective migration in two-dimensional (2D) in vitro assay. However, in 3D matrices, the level of Rho activation, although being disruptive for junctional stability, did not prevent their formation and cells still invaded in a collective manner. Furthermore, there is evidence that the CD151- $\alpha 3\beta 1$ complex plays a role in maintaining the integrity of ovarian carcinomas by repressing Slug-mediated EMT and canonical Wnt signaling [128]. Integrin $\alpha 3\beta 1$ -mediated cell-cell cohesion could hinder metastasis also in the context of passive tumor cell shedding to the blood stream. In line with this, tumor cells that have been released into the circulation of mice that contained induced (primary) renal tumors exhibited reduced levels of $\alpha 3\beta 1$ [141]. Thus, the role of the CD151- $\alpha 3\beta 1$ complex in carcinoma progression appears to be context-dependent and to depend on the mode of invasion and the phenotype of the tumor.

Association of α3β1 with uPAR

uPAR, the receptor for urokinase (uPA), is a glycosylphosphatidyl inositol-anchored protein expressed by many cell types. It forms complexes with several integrins, including $\alpha 3\beta 1$, and has been implicated in tumor progression (Fig. 2). In oral squamous cell carcinomas, increased expression of $\alpha 3\beta 1$ and uPAR correlates with a poor prognosis. In vitro and in vivo studies have shown that α3β1 clustering induces the recruitment of uPAR and the formation of $\alpha 3\beta 1$ -uPAR complexes that promote invasive cell behavior via Src and ERK1/2 signaling as well as via enhanced uPA expression [96,209]. In an independent study, it was shown that p130^{Cas} is phosphorylated by Src in response to uPAR-α3β1-laminin-332 engagement, and that this led to enhanced cell motility through activation of Cdc42 and actin reorganization [210]. Complexes of uPAR and α3β1 have also been implicated in the fibroblast associated protein α (FAPα)stimulated migration of ovarian cancer cells via activation of Rac1 [211]. In fact, an early study had already described that this complex can mediate binding to vitronectin [212]. Recently, an interesting novel mechanism was reported by Ferraris et al. [213], who showed that uPAR-mediated cell adhesion to vitronectin triggers integrin signaling independently of integrin-matrix engagement, by increasing the membrane tension. The same group also proposed that, in integrin ligand-independent conditions, the frictional membrane resistance participates in establishing adequate lamellipodial tension, which predominantly depends on coupling of the C-terminal talin-actin binding site to actomyosin-driven retrograde actin flow force [214]. This mechanism could provide an explanation for the role of uPAR-binding integrins, such as $\alpha 3\beta 1$, in migration in an environment lacking conventional integrin ligands.

Altered glycosylation of α3β1

The α3 and β1 subunits contain 14 and 12 potential N-glycosylation sites, respectively, and it has become increasingly clear that malignant transformation is associated with aberrant glycosylation of $\alpha 3\beta 1$, which can modulate its function, signaling and lateral associations with IAPs [215,216]. In bladder carcinomas, the overexpression of aberrantly glycosylated $\alpha 3\beta 1$ is correlated with poor clinical outcome, and a monoclonal antibody that recognizes the aberrantly glycosylated epitope on $\alpha 3\beta 1$ has potent anti-tumor activity in bladder cancer in vivo. In vitro experiments revealed that aberrant glycosylation of α3β1, conferred by the glycosyltransferase GALNT1, initiates FAK signaling, resulting in c-Jun phosphorylation and increased cell cycle progression, and proliferation through upregulation of cyclin D1 and activation of CDK4 [139]. Aberrant N-glycosylation of $\alpha 3\beta 1$ also influences the motility and invasiveness of cancer cells [217,218]. The presence of high mannose and sialylated tri- or tetraantennary complex type N-glycans on $\alpha 3\beta 1$ is associated with a reduced adhesion to laminin and an increased invasive behavior of bladder cancer cells [219,220]. Baldwin et al. [221] has shown that α3β1-mediated cell migration can also be influenced by N-glycosylation of $\alpha 3\beta 1$ without a detectable loss of cell adhesion to laminin-332. They found that the changes to N-glycosylation of α3β1, induced by its binding to CD151 during biosynthesis, influenced tumor cell migration toward laminin-332 [221]. The exact mechanism underlying the effect of α3β1 glycosylation on cell migration is unknown, but may involve galectin-3-mediated clustering of α3β1 and subsequent activation of Rac1 signaling [222]. Recently, a study was published proposing a role of N-glycosylation modifications in the efficient translocation of α3β1 to the plasma membrane [223]. Glycosylation of $\alpha 3\beta 1$ was observed to be suppressed by hypoxia, resulting in decreased levels of $\alpha 3\beta 1$ at the plasma membrane, which facilitated the invasion of epidermoid carcinoma cell line A431. There is therefore strong evidence that glycosylation of $\alpha 3\beta 1$ can play a role in promoting cell migration and invasiveness, as well as contribute to increased tumorigenesis.

Role of $\alpha 3\beta 1$ in gene regulation

As already mentioned, in transformed cells the expression of $\alpha 3\beta 1$ is often regulated to modulate its function. One of the examples of such regulation is mediated by transforming growth factor β (TGF- β). In invasive hepatocellular carcinoma cells, TGF- β stimulates the expression of $\alpha 3\beta 1$ by transcriptional upregulation via Ets transcription factors, resulting in a pro-invasive phenotype on laminin-332 [138,162]. Similar observations were reported in bladder cancer and in oral squamous carcinoma cells [224,225]. However, there is also an increasing amount of evidence for the role of $\alpha 3\beta 1$ in gene regulation and for the consequences this brings to the development and progression of tumors. $\alpha 3\beta 1$ -mediated gene regulation in the context of metastasis has

been recently reviewed [79] and will therefore only be briefly mentioned here. The most striking examples of the gene regulatory role of $\alpha 3\beta 1$ were observed in immortalized keratinocytes. In these cells α3β1 was shown to induce expression of MMP-9 upon transformation of cells [226], which was mediated via α3β1-dependent stabilization of MMP-9 mRNA transcripts [227]. Furthermore, the production of MMP-9 in immortalized keratinocytes was potentiated by $\alpha 3\beta 1$ in response to TGF- β stimulation [228]. The mechanism behind mRNA stabilization was recently proposed by Missan et al. [229]. who observed that a shorter, more stable mRNA was preferentially generated in immortalized keratinocytes expressing $\alpha 3\beta 1$. The presence of this short transcript was dependent on active ERK/MAPK signaling. Integrin α3β1 was also shown to influence the stability of COX-2 mRNA (discussed in chapter on proliferation and angiogenesis) and to regulate the expression of fibulin-2, a matrix-associated protein that binds laminin-332 and serves as a mediator of matrix remodeling and invasion [85]. In line with the latter, a recent study reported that α3β1 mediates the stability of the BM through fibulin-2 induction, indicating the importance of $\alpha 3\beta 1$ -mediated gene regulation not only in cancer progression, but also in maintenance of healthy tissue [230].

INTEGRIN α6β4 AND CANCER

Early studies have identified the integrin $\alpha6\beta4$ as a tumor antigen [231,232], whose expression is increased in squamous cell carcinomas, as well as in other types of solid cancers (reviewed in [233]). Some controversy exists regarding the stage of cancer development and progression at which $\beta4$ overexpression becomes apparent, but most studies agree that it increases with tumor grade [234,235]. In addition to increased expression of $\beta4$, changes in its distribution have also been linked to the grade of tumors [236,237]. In normal epithelial tissues, $\beta4$ is concentrated at the basal membrane of basal epithelial cells, while in many tumors, it is diffusely expressed in multiple cell layers [238–240]. Although abnormal and high expression of $\alpha6\beta4$ in cancer is generally associated with poor patient outcome and overall survival, in certain settings $\alpha6\beta4$ suppresses tumorigenesis. Furthermore, in tumors such as prostate carcinomas and basal cell carcinomas, the expression of $\alpha6\beta4$ is downregulated [241–245].

Different roles of $\alpha6\beta4$ in tumor development and progression might derive in part from its ability to assemble HDs. Additionally, $\alpha6\beta4$ may modulate oncogenic signaling by binding to its ligand laminin-332 in the ECM or through cooperative signaling with RTKs that stimulate or suppress proliferation. Finally, the role of $\alpha6\beta4$ depends on the ability of tumor cells to remodel the ECM and on their oncogene mutational profile.

Role of $\alpha 6\beta 4$ in tumor initiation

Although $\alpha 6\beta 4$ cannot induce tumorigenesis on its own [246], it has been implicated in human papilloma virus (HPV)-mediated tumor initiation. HPV plays a role in the initiation of several cancers such as anal, cervical and oropharyngeal cancer. Once the virus enters a cell, its proteins interfere with the normal cell machinery, which results in uncontrolled cell growth and avoidance of cell death. In HPV16 infected cervical cancer cells, $\alpha 6$ expression levels were correlated to the binding of the virus particles to the cells [247]. And in fact, it recently became clear that $\beta 4$ expression and $\alpha 6$ processing are important for HPV entry into the basal cells [248,249]. However, viral DNA replication occurs primarily in the differentiating suprabasal cells of the epidermis. The HPV E2 protein may trigger this differentiation step by downregulating $\beta 4$ expression [250,251]. These data strongly suggest that $\alpha 6\beta 4$ has a dual role in different stages of tumor initiation by HPV.

Role of $\alpha 6\beta 4$ in sustained proliferation and avoidance of apoptosis

The unique function of $\alpha6\beta4$ in potentiating growth factor receptor signaling is evident from its role in supporting sustained proliferation and avoidance of apoptosis during tumor development and progression. Integrin $\alpha6\beta4$ has been implicated in the modulation of signal transduction pathways downstream of several RTKs, including the epidermal growth factor receptor (EGFR) family members EGFR [65] and ErbB-2 [252,253], the macrophage stimulating protein (MSP) receptor (also known as Ron) [254], the hepatocyte growth factor (HGF) receptor (also called c-Met) [71,255] and the insulin-like growth factor-1 receptor [256].

Many studies attribute the synergy between $\alpha6\beta4$ and RTK-mediated signaling to the phosphorylation of specific tyrosine residues in the cytoplasmic domain of $\beta4$ and subsequent recruitment and activation of signaling intermediates to the phosphorylated subunit (reviewed in [257]). The C-terminal segment of the $\beta4$ cytoplasmic domain that harbors the tyrosine residues is also known as the $\beta4$ signaling domain. Tyrosine phosphorylation of $\beta4$ is typically mediated by the Src family of kinases (SFKs) downstream of RTKs [254,258,259], although direct tyrosine phosphorylation of $\beta4$ by the HGF receptor c-Met has also been demonstrated [260]. Additionally, clustering of the $\alpha6\beta4$ molecules by itself can lead to tyrosine phosphorylation of the $\beta4$ subunit [261]. Recent data suggests that members of the syndecan family of cell-surface proteoglycans may play an important role in the phosphorylation of the $\beta4$ cytoplasmic domain by positioning this domain near the plasma membrane to be phosphorylated by the SFK member Fyn downstream of EGFR and ErbB-2. Syndecans can bind directly to the cytoplasmic domain of the $\beta4$ subunit [262,263].

The signaling intermediates that are recruited by tyrosine phosphorylated β4 include the adapter proteins Shc [260,264] and IRS-1/2 [70], and the protein-tyrosine phosphatase Shp2 (also known as PTPN11) [71]. Binding of Shc by tyrosine phosphorylated $\beta4$ has been shown in squamous carcinoma cells expressing the EGFR at high levels [260], but also upon EGF treatment of cells that express normal levels of the EGFR [258]. Shc links α6β4 to the MAPK signaling pathway, which is essential for inducing cellular proliferation and transformation [264]. On the other hand, c-Met-mediated tyrosine phosphorylation of 84 has been shown to recruit Shp2, which enhances the activation of Src. Subsequently, Src induces the phosphorylation of the multi-adapter Gab1, which leads to activation of the MAPK and phosphatidylinositol 3-kinase (PI3K) signaling pathways [71,255]. Activation of MAPK signaling can also be mediated by a fraction of α6β4 that is localized in lipid rafts and associated with palmitoylated SFKs [265]. Binding of IRS-1/2 by tyrosine-phosphorylated β4 has also been implicated in the activation of PI3K downstream of $\alpha6\beta4$ clustering [70]. Furthermore, there is data suggesting that FAK can be recruited by tyrosine phosphorylated $\beta4$ and that the subsequent activation of FAK promotes malignancy by increasing the activity of p38MAPK and Akt [259]. Tyrosine phosphorylation of B4 and subsequent activation of PI3K signaling can also promote the survival of breast cancer cells through enhanced VEGF translation and stimulation of VEGFR-mediated autocrine signaling [266] (reviewed in [267]).

Most studies agree that $\alpha6\beta4$ supports PI3K activation by different RTKs, although the details of the mechanisms may differ between cell types. Activation of PI3K by $\alpha6\beta4$ -mediated cell adhesion was first shown by Shaw *et al.* [268], and since then, numerous other studies have reported an association between $\alpha6\beta4$ -mediated adhesion and the requirement of PI3K activation for cell survival. In breast cancer cells, blocking $\alpha6\beta4$ function with an antibody against $\beta4$ caused a reduction in PI3K signaling, which led to increased apoptosis [269]. The induced apoptosis could be rescued by the expression of constitutively active Akt, the downstream target of PI3K [269,270]. Integrin $\alpha6\beta4$ -mediated PI3K signaling can also support cell survival through activation of the transcription factors STAT3 and c-Jun, as was shown in an ErbB-2-driven breast cancer mouse model [252].

Intriguingly, it has been reported that $\alpha6\beta4$ can also promote cell death. *In vitro*, treatment of cells with chemical or pharmacological agents induced apoptosis via elevating the levels of $\beta4$, while the depletion of $\beta4$ promoted survival [271–275]. Furthermore, in an immunocompromised SCID mouse model of human gastric cancer, the expression of $\beta4$ at high levels promoted apoptosis [276]. Bachelder *et al.* [277] suggested that the ability of $\alpha6\beta4$ to either promote or suppress apoptosis depends on the p53 status of the cells. Integrin $\alpha6\beta4$ stimulates p53-transactivating function

and promotes p53-dependent apoptosis in carcinoma cells that express wild-type p53, but not in p53-deficient carcinoma cells, in which it promotes survival in a Pl3K/Akt dependent manner. Interestingly, in the same colon carcinoma cells depletion of p53 associates also with enhanced $\beta4$ transcription through the p53 family members p63 and p73, thereby further augmenting the survival function of $\alpha6\beta4$ [278]. Although the inhibition of $\alpha6\beta4$ -mediated survival signaling by p53 activation has so far been only conclusively shown in RKO colon carcinoma cells [279], the fact that p53 mutations and overexpression of $\alpha6\beta4$ are positively correlated in a number of human malignancies [233] suggests a general mechanism by which the activity of p53 in carcinoma cells is regulated by the signaling function of this integrin. Interestingly, p53 has also been suggested to regulate adhesion of cancer cells via $\alpha6\beta4$ [280].

In addition to supporting cell proliferation and survival by providing an additional platform for RTK signaling, $\alpha6\beta4$ may be needed to secure attachment during oncogenic transformation when the adhesive function of integrins that are linked to the actin cytoskeleton is compromised, while oncogenic signaling is still dependent on the structural integrity of the actin cytoskeleton. This might be responsible for the requirement of the presence of $\alpha6\beta4$ and its ligand laminin-332 in squamous cell carcinomas, induced by oncogenic Ras and IkB α expression [281]. Similarly, the promotion of cell growth by $\alpha6\beta4$, which was reported to be anchorage-independent [71,282], could still have been dependent on $\alpha6\beta4$ -mediated adhesion to autocrine-produced laminin. In support of this notion, in 3D culture of mammary spheroids, $\alpha6\beta4$ -mediated cell adhesion to autocrine produced laminin-332 conferred resistance to apoptosis by stimulating Rac1-Pak signaling and activation of NF-kB [283,284]. Moreover, Bertotti *et al.* [255] showed that the removal of the extracellular domain of $\beta4$ reduced anchorage-independent colony formation in soft agar.

Additionally, it has been suggested that suprabasal $\alpha6\beta4$ contributes to cancer progression by enhancing proliferation of basal keratinocytes by relieving the growth inhibition of TGF- β [246]. TGF- β negatively regulates keratinocyte proliferation in the early stages of epidermal tumor promotion [285,286]. This growth inhibitory effect of TGF- β is dependent on cadherin-mediated cell-cell adhesion and PI3K, but not MAPK activity. Suprabasal $\alpha6\beta4$ appears to perturb TGF- β signaling by blocking nuclear translocation of activated Smad2/3, resulting in increased cell proliferation and formation of skin papillomas and SCCs [246]. Surprisingly, tumorigenesis was further increased when mice expressed a mutant $\beta4$ subunit that lacked the cytoplasmic domain in the suprabasal layers of the epidermis, suggesting that $\alpha6$, rather than $\beta4$ cytoplasmic domain might play a role in TGF- β signaling [246].

Role of α6β4 in angiogenesis

Within the vasculature, the expression of $\alpha6\beta4$ in endothelial cells is dynamically regulated during angiogenesis and vessel maturation [287]. α6β4 is predominantly detected in small arterial vessels, where it may mediate strong endothelial cell adhesion, necessary to withstand the high shear rates in these vessels [19]. Contrary to β 4, α 6 is expressed in all vasculature, which suggests the presence of α 6 β 1 in the absence of β4 [19,288]. Integrin α6β1 is known to promote angiogenesis; inhibition of α6 prevented endothelial cell migration and tube formation [289]. However, the role of $\beta 4$ in angiogenesis is less clear. The exclusive presence of $\beta 4$ in mature vessels suggests that it negatively regulates angiogenesis [287], and several studies report that $\alpha684$ does not promote endothelial cell proliferation or growth of new vessels [19,287,290]. Furthermore, it has been recently suggested that downregulation of α6β4 is necessary for endothelial proliferation and tube formation during early stages of angiogenesis [288]. In line with this notion it was proposed that α6β4 can block angiogenesis by inducing endothelial cell death [291] (reviewed in [292]). On the other hand, experiments in mice in which the C-terminal domain of β4 was deleted, showed that α6β4 signaling is important for vascular remodeling and for a proficient angiogenic response to VEGF and basic fibroblast growth factor (bFGF) [290]. Furthermore, in mice lacking β 4 in endothelial cells, hypoxia-induced arteriolar remodeling was defective, which was suggested to result from changed TGF-β signaling [19]. Alternatively, β4 can regulate angiogenesis via stimulation of translation and signaling of VEGF [266,293] (Fig. 3).

Although $\alpha6\beta4$ seems to play a general regulatory role in angiogenesis, there is very little known about its role in tumor angiogenesis. In mice, carrying a deletion of the C-terminal domain of $\beta4$, vascularization in subcutaneously implanted tumors was impaired, suggesting that $\alpha6\beta4$ promotes tumor angiogenesis [290]. However, the levels of tumor vascularization in a mammary gland tumor model were the same in mice carrying a similar $\beta4$ deletion as in $\beta4$ wild-type mice [252].

Role of $\alpha6\beta4$ in invasion and metastasis

Unlike that of $\alpha 3\beta 1$, the expression of $\alpha 6\beta 4$ is positively correlated with tumor grade in most instances, indicating that this integrin promotes tumor progression and metastatic spread. The role of $\alpha 6\beta 4$ in invasion and metastasis has been reviewed extensively over the last two decades, in articles primarily focusing on the mechanisms responsible for its tumor-promoting function [67,68,233,294,295]. However, there are certain cases in which $\alpha 6\beta 4$ is negatively correlated with tumor invasion and formation of metastases. In order to elucidate the circumstances that determine the function of $\alpha 6\beta 4$ in the final stages of cancer, it is important to understand under which conditions it contributes

to cellular migration and invasion, as well as to understand the differences between tumor settings, in which the role of $\alpha 6\beta 4$ has been implicated.




Figure 3: Integrin α 6 β 4 regulates cell behavior by cooperating with RTKs. Integrin α 6 β 4 amplifies intracellular signaling of RTKs. SFK that are activated by RTKs phosphorylate several tyrosine residues (red dots) in the signaling domain of the β 4 cytoplasmic tail. These tyrosine residues act as docking site for adaptor proteins to activate the PI3K and MAPK signaling pathways. Activated PI3K and MAPK further regulate cell migration, proliferation, angiogenesis, apoptosis, invasion and survival via activation of downstream effectors, by regulating cell-cell adhesion or via regulation of gene expression by transcription factors. RTK, receptor tyrosine kinase; SFK, Src family kinase; PI3K, phosphoinositide 3-kinase; MAPK, mitogen-activated protein kinases; TFs, transcription factors.

Migration and invasion

It is generally accepted that HDs have to be disassembled before cells can migrate (**Fig. 4**). Indeed, studies using primary keratinocytes have revealed that classical HDs (type I HDs), which contain $\alpha6\beta4$, CD151, plectin, BP180 and BP230, prevent cell migration [296,297]. However, $\alpha6\beta4$ does not necessarily impede cell migration as part of type II HDs, a less complex type of HDs that only contains $\alpha6\beta4$ and plectin [298]. Type II HDs are found in simple epithelia and many cultured epithelial cells, and in contrast to type I HDs, their components have a turnover rate that is fast enough not to limit the migration of cells [50,52,299].

In many transformed cells the number of HDs is reduced and they are completely and/or partially disassembled. In these cells, $\alpha6\beta4$ facilitates growth-factor stimulated migration and invasion via its cytoplasmic domain (reviewed in [47]). Induction of carcinoma cell migration by EGF is associated with a redistribution of $\alpha6\beta4$ from HDs to the leading edge of the cell (reviewed in [67]), where it colocalizes with actin in lamellipodia and filopodia [53,54]. How $\alpha6\beta4$ associates with actin and how this contributes to migration is not clear. Like α3β1, α6β4 has been implicated in actin cytoskeletal dynamics during migration through the regulation of the Rho family of GTPases [300,301]. Although RhoA plays a crucial role in the retraction of the tail of the cells, both Rac1 and RhoA are required for stimulating cell migration on 2D substrates by inducing the formation of actin-based protrusive structures [302]. Rac1, which is activated by α6β4-mediated cell adhesion, promotes the formation of lamellipodia and, interestingly, the localization of $\alpha 3\beta 1$ in these structures [303]. Integrin α6β4 supports PI3K-Rac1 signaling [268] downstream of several pro-migratory factors (e.g. EGF [304], HGF [305], PTHrP (parathyroid hormone-related protein) [306] and LPA (lysophosphatidic acid) [307]) (Fig. 3). EGF-induced activation of Rac1 requires both the extracellular and the cytoplasmic domain of the β4 subunit [304]. On the other hand, when it is part of HDs, ligation of $\alpha6\beta4$ by laminin activates Rac1 independently of the signaling domain of \(\text{B4 [308,309]}. \) In addition to stimulating migration by increasing the activity of Rac1 in tumor cells, $\alpha6\beta4$ has also been implicated in augmenting the activity of RhoA by a mechanism that involves suppression of the intracellular cAMP concentration by activating a cAMP specific phosphodiesterase [261,310].

Several studies have shown that $\alpha6\beta4$ influences migration and invasion of tumor cells through the NFAT (nuclear factor of activated T-cells) transcription factors [311] (**Fig. 3**), which are activated downstream of Src and PI3K/Akt signaling [312](reviewed in [67]). $\alpha6\beta4$ -mediated activation of NFAT1 induces the transcription of autotaxin [313], which promotes LPA-induced cell motility and invasiveness [314]. In line with this, $\alpha6\beta4$ -mediated cell motility was decreased in breast carcinoma cells that were depleted of autotaxin [313]. NFAT5, a transcription factor responsible for the upregulation of the calcium-binding protein S100A4, can also be activated by $\alpha6\beta4$ -mediated cell adhesion [315]. S100A4 is a metastasis-promoting protein implicated in the invasion of a number of tumor types including colon and breast carcinomas (reviewed in [316,317]). Another protein that plays a role in the calcium-dependent regulation of migration is the transient receptor potential vanilloid channel (TRPV1). In the absence of TRPV1, both directional migration and $\beta4$ expression are reduced [318].

Several studies suggested that $\alpha6\beta4$ can influence ovarian and breast cancer cell migration and invasion through the activation of FAK [259,319]. $\alpha6\beta4$ -mediated FAK activation was

observed upon ligation of $\alpha6\beta4$ to laminin-332, but also to alternative ligands, such as CLCA1 and MUC5Ac [320,321]. Recent findings have shown that FAK can directly bind to $\beta4$ and suggest that this association is regulated by tyrosine phosphorylation of the $\beta4$ subunit [259].

During invasion, the ECM is often remodeled, enabling tumor cells to efficiently migrate and disseminate. $\alpha6\beta4$ has been implicated in ECM remodeling through its ability to contribute to the activation of PI3K and RhoA, and subsequent induction of traction forces generated by the actomyosin cytoskeleton [322,323]. Additionally, $\alpha6\beta4$ plays a role in remodeling of the ECM by supporting signals that lead to the production of MMP1 and MMP2 [325,326]. MMP levels can also be induced by several of its interactors, such as CD151 (reviewed in [327–329]).

Metastasis – intravasation, extravasation and niche preparation

Many studies have demonstrated a critical role of $\alpha6\beta4$ in promoting the formation of metastases (reviewed in [78,330,331]). Moreover, $\alpha6\beta4$ serves as a marker to detect distant metastases in the early stages of specific malignancies [101,332,333]. However, the mechanism underlying its pro-metastatic role has received little attention. Metastases occur when cancer cells invade into the blood or lymph vessels, travel through these systems and subsequently extravasate into the stroma of the target organ. $\alpha6\beta4$ contributes to intravasation and extravasation of tumor cells by upregulating VEGF expression (**Fig. 3**), which enhances transendothelial permeability and migration of malignant cells [334–337]. The effect of $\alpha6\beta4$ on VEGF expression appeared to be dependent on the signaling domain of $\beta4$ [337].

Following extravasation, tumor cells need to adhere, proliferate and grow in the new environment (*i.e.* the metastatic niche) in order to form a metastasis. Cells from specific tumors tend to form metastasis in certain organs. Recently, Hoshino *et al.* [338] suggested that exosomes can contribute to the formation of a metastatic niche in specific organs. They showed that expression of $\alpha6\beta4$ and $\alpha6\beta1$ on exosomes was associated with lung metastases in mice, and that blocking of exosomal $\alpha6\beta4$ decreased the formation of such metastases.




Figure 4: Integrin $\alpha6\beta4$ regulates adhesion and migration by the formation of HDs. Type I HDs contribute to stable adhesion of basal epithelial cells to laminin-332 in the basement membrane and therefore inhibit cell migration. Although type II HDs contribute to adhesion as well, they are more dynamic and do not impede migration. In migrating cells, HDs are disassembled and $\alpha6\beta4$ is suggested to be associated with the actin cytoskeleton. HD, hemidesmosome.

Crosstalk with growth factors and hormones

The crosstalk between q6B4 and growth factor receptors not only plays a role in tumor growth (see previous chapters), but also strongly contributes to the $\alpha6\beta4$ -mediated tumor invasion, metastasis formation and cell migration. The synergy between $\alpha6\beta4$ and several RTKs (e.g. c-Met [260,268], Ron [254,339], ErbB-2 [340], EGFR [258] and ErbB-3 [341]) primarily promotes tumor spreading and invasion. This tumor promoting function of $\alpha6\beta4$, like its promotion of tumor growth, often involves the disassembly of HDs and subsequent β4-mediated signaling (reviewed in [47,68,80,342,343]). Additionally, α6β4 can have an impact on invasion and metastasis through regulating cell-cell junctions [252] (Fig. 3). In ErbB-2 transformed mammary epithelial cells, β4 promotes invasion and metastasis by disorganizing cell-cell junctions via SFK-dependent ErbB-2 activation of STAT3. Accordingly, in these cells the loss of β4 signaling restores cell-cell adhesion, and as a consequence cell invasion is compromised. However, this negative effect of β4 on cell-cell contacts is only seen in the presence of receptors of the EGFR family, and blocking these receptors promotes reassembly of cell-cell junctions [252]. Like $\alpha 3\beta 1$, $\alpha 6\beta 4$ was reported to promote the formation of cadherin dependent cell-cell junctions, resulting in restrained cell migration [344,345]. Furthermore, upon induction of EMT by TGF-β a decrease in E-cadherin expression has been correlated with a reduction of the levels of $\beta 4$ [346]. Such a reduction has also been shown in carcinoma cells in which EMT was induced by overexpression of Snail [347]. In contrast, suppression of the EMT regulator Slug resulted in a reduction of the $\alpha 6\beta 4$ levels [348]. In addition to the reduced levels of $\beta 4$ in tumor cells, which have undergone an EMT, there is evidence that $\beta 4$ is less sialylated during EMT, which may further decrease the tumor promoting capacity of this integrin [349,350].

Besides a signaling cooperation between $\alpha6\beta4$ and growth factor receptors, there is also crosstalk between $\alpha6\beta4$ and hormones during tumor progression. Estrogen and PTHrP signaling was shown to enhance the pro-tumorigenic effects of $\alpha6\beta4$ [351,352]. On the other hand, the expression of $\beta4$ in prostate cancer is reduced by the androgen receptor and the absence of $\beta4$ in the androgen-sensitive tumors reduces their invasiveness [353,354].

Targeted disruption of the crosstalk between $\alpha6\beta4$ and growth factor receptors or between $\alpha6\beta4$ and hormone receptors has been recognized as a potential form of therapy in the treatment of cancer [252,341,355]. However, because of its dual role in tumor development and promotion, targeting $\beta4$ can only be beneficial under well-defined and specific circumstances. In certain cancers, such as gastric carcinomas, the degree of $\beta4$ expression is inversely correlated with invasive potential and blocking $\beta4$ function would likely increase the tumor burden [276]. Furthermore, the analysis of transformed keratinocytes suggests that blocking the function of $\beta4$ in the early-stages of tumorigenesis might promote the disease [356].

Regulation of β 4 expression

As previously discussed, the expression of $\beta 4$ is frequently upregulated in cancer. For example, hypoxia increases the surface expression of $\alpha 6\beta 4$ by promoting Rab11-dependent trafficking, resulting in increased breast tumor cell invasion [43]. Other factors and proteins implicated in the expression of $\beta 4$ in tumors include Rac1 [357], TR3/Nur77 [358], PTHrP [352,359,360], IL24 [361] and H-Ras [362], ARRDC3 [363] and ZEB1 [364]. Expression of $\alpha 6\beta 4$ is also regulated by palmitoylation of the $\alpha 6$ and $\alpha 6 4$ subunits and ablation of the protein acyl transferase, responsible for their palmitoylation results in accelerated degradation of $\alpha 6\beta 4$ [365]. miRNAs have emerged in the past decade as key regulators of gene expression. They repress gene expression by blocking mRNA translation or promoting mRNA degradation [366]. Several miRNAs have been reported to regulate expression of $\alpha 6\beta 4$. Overexpression of miR-221 and miR-222 resulted in reduced $\alpha 6\beta 4$ expression, which was partially responsible for impaired invasion of breast cancer cells [367], while in the absence of miR-21 a higher expression level of $\alpha 6\beta 4$ was correlated with a reduction in the rate of colorectal cancer cell migration

[366]. Furthermore, loss of miR-205 in prostate cancer resulted in reduced secretion of laminin-332 and $\beta 4$ *in vitro* [368]. Therefore, the different expression patterns of $\beta 4$ in cancer might be explained, at least to some extent, by specific miRNAs present in the different tissues.

Role of CD151 and $\alpha 6$ in $\alpha 6\beta 4$ -regulated tumorigenesis

Most studies have focused on the role of $\alpha6\beta4$ in cancer without considering the fact that two isoforms of the α6 cytoplasmic domain (i.e. A and B) can be generated by alternative splicing [13,16]. In colorectal carcinomas, in which both a relative decrease and increase of 84 expression was observed during malignant transformation [369,370], the tumorigenic outcome of B4 positive cancers was dependent on which isoform of the α6 subunit was associated with β4 [371]. A relationship between the expression of specific α6 isoforms and tumor malignancy has also been observed in skin tumorigenesis [372]. As well as forming dimers with the β4 subunit, the α6 subunit can also dimerize with $\beta 1$ to form the $\alpha 6\beta 1$ heterodimer, which has a tumor promoting role and is correlated with a poor prognosis (discussed in introduction) [373]. Similar to $\alpha6\beta4$, the role of $\alpha6\beta1$ in cancer can be dependent on $\alpha6$ isoform expression [374,375]. α6β1 and α6β4 are co-expressed in numerous cell lines. However, the ratio of these complexes varies considerably from one cell line to another [21]. Since α 6 preferentially binds to the β4 subunit [231,376], the absence of β4 might lead to a switch from α6β4 to α6β1, and thus to promoting carcinogenesis in an α6β1-dependent manner. A switch from α6β4 to α6β1 has been observed during prostate cancer progression, in which expression of the androgen receptor suppresses α6β4 expression [241].

We have already discussed the impact of CD151- α 3 β 1 on tumor progression. However, CD151 can also bind α 6 and the presence of CD151- α 6 β 4 in breast cancer was associated with tumor progression [204,377]. CD151 may affect the function of α 6 β 4 through its association with PI4K or by regulating α 6 β 4 trafficking, its incorporation into TEMs and/ or its ligand binding activity [192,194,378]. Recently, it has been shown that CD151 is also involved in the crosstalk between α 6 β 4 and RTKs [204,379] and that deletion of CD151 reduces β 4 phosphorylation at specific serine residues [377,380]. These serine residues have been previously implicated in the regulation of the interaction between α 6 β 4 and plectin [50,381]. While the interaction between α 6 β 4 and CD151 is well-established, there is data supporting that α 6 β 4 can also form complexes with two other tetraspanins (D6.1A and CD9) and thus might also influence tumorigenesis by interacting with these molecules [382,383].

CONCLUSIONS

The importance of laminin-binding integrins in the development and progression of tumors has been demonstrated in many studies. However, the role they play during these processes is complex, and possibly determined by several intra- and extracellular factors. Among the factors that have been shown to impact the outcome of tumor cells expressing laminin-binding integrins are the oncogenic profile and the nature of the tumor cells (e.g. secretion of hormones, presence of different membrane receptors, hypoxia, etc.), the presence of different ECM components (especially laminins), and the regulation of posttranslational modifications of the integrins.

Integrins influence multiple aspects of tumorigenesis through their impact on adhesion and their ability to enhance signaling pathways downstream of RTKs. One of the features of laminin-binding integrins that strongly influences tumorigenesis and tumor progression is their ability to mediate bi-directional signaling with small GTPases and to promote cytoskeletal remodeling. Several decades ago it was already known that tension-dependent changes in cell shape are necessary for progression of the cell cycle [384], and since then numerous studies have shown that integrin-mediated adhesion and spreading of cells is essential for nuclear translocation of transcription factors [309,385,386]. Therefore, the activation of GTPases by either $\alpha 3\beta 1$ - or $\alpha 6\beta 4$ -mediated cell adhesion not only influences tumor cell migration and invasion, but may also enable nuclear translocation of transcription factors to promote proliferation and survival of tumor cells that have not yet acquired the ability to grow anchorage independent. Furthermore, adhesion mediated by laminin-binding integrins, especially $\alpha 6\beta 4$, might be essential for tumor development and progression simply by promoting pro-oncogenic signaling pathways.

The pro-migratory role of laminin-binding integrins is often connected to their ability to support PI3K-Rac1 signaling, which might be due to a lack of association of these integrins with the actomyosin cytoskeleton. Integrin $\alpha 6\beta 4$ is connected with the intermediate filament system in type I and type II HDs, while $\alpha 3\beta 1$, when associated with CD151, is incorporated into TEMs. Activation of Rac1 by either $\alpha 3\beta 1$ - or $\alpha 6\beta 4$ -mediated cell adhesion most likely occurs through synergy with aberrantly expressed and activated RTKs. Additionally, two tyrosine phosphorylation sites in the third fibronectin type III repeat of the $\beta 4$ cytoplasmic domain (*i.e.* Y1494 and Y1526) have been reported to be sufficient for the activation of Rac [69,387]. Although these residues are located in NXXpY motifs, their structural environments are not compatible with binding to the PTB and SH2 binding domains of Shp2 and Shc, respectively [388]. The relevance of this mode of signaling therefore remains debatable.

Finally, the crosstalk between laminin-binding integrins and RTKs, and their association with IAPs, are the key determinants of the role of integrins in modulating cell behavior. As discussed in length above, $\alpha 3\beta 1$ and $\alpha 6\beta 4$ can interact with several different proteins. Therefore, it is very likely that a crosstalk between integrins and several different RTKs occurs in individual cells, and that several different $\alpha 3\beta 1$ or $\alpha 6\beta 4$ integrin-containing complexes exist simultaneously. However, little is known about the localization of these complexes, or how these different complexes interact. Therefore, a better understanding of how the balance between these complexes is established and how they influence oncogenic signaling pathways in cells will be necessary to fully understand the role of laminin-binding integrins in the development and progression of tumors.

ACKNOWLEDGMENTS

We thank Elisabetta Argenzio, Spiros Pachis, Paul Engelfriet, Kevin Wilhelmsen and Alba Zuidema, for their helpful comments on the manuscript. We also thank the Dutch Cancer Society for financial support.

REFERENCES

- [1] M. Durbeej, Laminins, Cell Tissue Res. 339 (2010) 59–268. doi:10.1007/s00441-009-0838-2.
- [2] M.B. Srichai, R. Zent, Integrin Structure and Function, in: R. Zent, A. Pozzi (Eds.), Cell-Extracell. Matrix Interact. Cancer, Springer New York, 2010: pp. 19–41. http://link.springer.com/chapter/10.1007/978-1-4419-0814-8. 2 (accessed February 19, 2016).
- [3] R. Nishiuchi, J. Takagi, M. Hayashi, H. Ido, Y. Yagi, N. Sanzen, T. Tsuji, M. Yamada, K. Sekiguchi, Ligand-binding specificities of laminin-binding integrins: a comprehensive survey of laminin-integrin interactions using recombinant alpha3beta1, alpha6beta1, alpha7beta1 and alpha6beta4 integrins, Matrix Biol. J. Int. Soc. Matrix Biol. 25 (2006) 189–197. doi:10.1016/j.matbio.2005.12.001.
- [4] Y. Kikkawa, N. Sanzen, H. Fujiwara, A. Sonnenberg, K. Sekiguchi, Integrin binding specificity of laminin-10/11: laminin-10/11 are recognized by alpha 3 beta 1, alpha 6 beta 1 and alpha 6 beta 4 integrins, J. Cell Sci. 113 (Pt 5) (2000) 869–876.
- [5] G.O. Delwel, A.A. de Melker, F. Hogervorst, L.H. Jaspars, D.L. Fles, I. Kuikman, A. Lindblom, M. Paulsson, R. Timpl, A. Sonnenberg, Distinct and overlapping ligand specificities of the alpha 3A beta 1 and alpha 6A beta 1 integrins: recognition of laminin isoforms, Mol. Biol. Cell. 5 (1994) 203–215.
- [6] A.A. de Melker, A. Sonnenberg, Integrins: alternative splicing as a mechanism to regulate ligand binding and integrin signaling events, BioEssays News Rev. Mol. Cell. Dev. Biol. 21 (1999) 499–509. doi:10.1002/(SICI)1521-1878(199906)21:6<499::AID-BIES6>3.0.CO;2-D.
- [7] M. Kääriäinen, L. Nissinen, S. Kaufman, A. Sonnenberg, M. Järvinen, J. Heino, H. Kalimo, Expression of alpha7beta1 integrin splicing variants during skeletal muscle regeneration, Am. J. Pathol. 161 (2002) 1023–1031.
- [8] N. Vignier, B. Moghadaszadeh, F. Gary, J. Beckmann, U. Mayer, P. Guicheney, Structure, genetic localization, and identification of the cardiac and skeletal muscle transcripts of the human integrin alpha7 gene (ITGA7), Biochem. Biophys. Res. Commun. 260 (1999) 357–364. doi:10.1006/ bbrc.1999.0916.
- [9] C.M. DiPersio, J.E. Trevithick, R.O. Hynes, Functional comparison of the alpha3A and alpha3B cytoplasmic domain variants of the chicken alpha3 integrin subunit, Exp. Cell Res. 268 (2001) 45–60. doi:10.1006/excr.2001.5273.
- [10] A.A. de Melker, L.M. Sterk, G.O. Delwel, D.L. Fles, H. Daams, J.J. Weening, A. Sonnenberg, The A and B variants of the alpha 3 integrin subunit: tissue distribution and functional characterization, Lab. Investig. J. Tech. Methods Pathol. 76 (1997) 547–563.
- [11] G.O. Delwel, I. Kuikman, A. Sonnenberg, An alternatively spliced exon in the extracellular domain of the human alpha 6 integrin subunit--functional analysis of the alpha 6 integrin variants, Cell Adhes. Commun. 3 (1995) 143–161.
- [12] F. Hogervorst, L.G. Admiraal, C. Niessen, I. Kuikman, H. Janssen, H. Daams, A. Sonnenberg, Biochemical characterization and tissue distribution of the A and B variants of the integrin alpha 6 subunit, J. Cell Biol. 121 (1993) 179–191.
- [13] F. Hogervorst, I. Kuikman, A.G. van Kessel, A. Sonnenberg, Molecular cloning of the human alpha 6 integrin subunit. Alternative splicing of alpha 6 mRNA and chromosomal localization of the alpha 6 and beta 4 genes, Eur. J. Biochem. FEBS. 199 (1991) 425–433.
- [14] B.L. Ziober, M.P. Vu, N. Waleh, J. Crawford, C.S. Lin, R.H. Kramer, Alternative extracellular and cytoplasmic domains of the integrin alpha 7 subunit are differentially expressed during development, J. Biol. Chem. 268 (1993) 26773–26783.
- [15] S. Thorsteinsdóttir, B.A. Roelen, E. Freund, A.C. Gaspar, A. Sonnenberg, C.L. Mummery, Expression patterns of laminin receptor splice variants alpha 6A beta 1 and alpha 6B beta 1 suggest different roles in mouse development, Dev. Dyn. Off. Publ. Am. Assoc. Anat. 204 (1995) 240–258. doi:10.1002/aja.1002040304.

- [16] R.N. Tamura, H.M. Cooper, G. Collo, V. Quaranta, Cell type-specific integrin variants with alternative alpha chain cytoplasmic domains, Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 10183–10187.
- [17] C. Gimond, C. Baudoin, R. van der Neut, D. Kramer, J. Calafat, A. Sonnenberg, Cre-loxP-mediated inactivation of the alpha6A integrin splice variant in vivo: evidence for a specific functional role of alpha6A in lymphocyte migration but not in heart development, I. Cell Biol. 143 (1998) 253–266.
- [18] T. Velling, G. Collo, L. Sorokin, M. Durbeej, H. Zhang, D. Gullberg, Distinct alpha 7A beta 1 and alpha 7B beta 1 integrin expression patterns during mouse development: alpha 7A is restricted to skeletal muscle but alpha 7B is expressed in striated muscle, vasculature, and nervous system, Dev. Dyn. Off. Publ. Am. Assoc. Anat. 207 (1996) 355–371. doi:10.1002/(SICI)1097-0177(199612)207:4<355::AID-AJA1>3.0.CO;2-G.
- [19] J.V. Welser-Alves, A. Boroujerdi, U. Tigges, L. Wrabetz, M.L. Feltri, R. Milner, Endothelial β4 integrin is predominantly expressed in arterioles, where it promotes vascular remodeling in the hypoxic brain, Arterioscler. Thromb. Vasc. Biol. 33 (2013). doi:10.1161/ATVBAHA.112.300566.
- [20] C.M. Niessen, O. Cremona, H. Daams, S. Ferraresi, A. Sonnenberg, P.C. Marchisio, Expression of the integrin alpha 6 beta 4 in peripheral nerves: localization in Schwann and perineural cells and different variants of the beta 4 subunit, J. Cell Sci. 107 (Pt 2) (1994) 543–552.
- [21] A. Sonnenberg, C.J. Linders, J.H. Daams, S.J. Kennel, The alpha 6 beta 1 (VLA-6) and alpha 6 beta 4 protein complexes: tissue distribution and biochemical properties, J. Cell Sci. 96 (Pt 2) (1990) 207–217.
- [22] R.Q. Schaapveld, L. Borradori, D. Geerts, M.R. van Leusden, I. Kuikman, M.G. Nievers, C.M. Niessen, R.D. Steenbergen, P.J. Snijders, A. Sonnenberg, Hemidesmosome formation is initiated by the beta4 integrin subunit, requires complex formation of beta4 and HD1/plectin, and involves a direct interaction between beta4 and the bullous pemphigoid antigen 180, J. Cell Biol. 142 (1998) 271–284.
- [23] F. Vidal, D. Aberdam, C. Miquel, A.M. Christiano, L. Pulkkinen, J. Uitto, J.P. Ortonne, G. Meneguzzi, Integrin beta 4 mutations associated with junctional epidermolysis bullosa with pyloric atresia, Nat. Genet. 10 (1995) 229–234. doi:10.1038/ng0695-229.
- [24] R. van der Neut, P. Krimpenfort, J. Calafat, C.M. Niessen, A. Sonnenberg, Epithelial detachment due to absence of hemidesmosomes in integrin beta 4 null mice, Nat. Genet. 13 (1996) 366–369. doi:10.1038/ng0796-366.
- [25] J. Dowling, Q.C. Yu, E. Fuchs, Beta4 integrin is required for hemidesmosome formation, cell adhesion and cell survival, J. Cell Biol. 134 (1996) 559–572.
- [26] E. Georges-Labouesse, N. Messaddeq, G. Yehia, L. Cadalbert, A. Dierich, M. Le Meur, Absence of integrin alpha 6 leads to epidermolysis bullosa and neonatal death in mice, Nat. Genet. 13 (1996) 370–373. doi:10.1038/ng0796-370.
- [27] N. Nicolaou, C. Margadant, S.H. Kevelam, M.R. Lilien, M.J.S. Oosterveld, M. Kreft, A.M. van Eerde, R. Pfundt, P.A. Terhal, B. van der Zwaag, P.G.J. Nikkels, N. Sachs, R. Goldschmeding, N.V.A.M. Knoers, K.Y. Renkema, A. Sonnenberg, Gain of glycosylation in integrin α3 causes lung disease and nephrotic syndrome, J. Clin. Invest. 122 (2012) 4375–4387. doi:10.1172/JCI64100.
- [28] E.G. Yalcin, Y. He, D. Orhan, C. Pazzagli, N. Emiralioglu, C. Has, Crucial role of posttranslational modifications of integrin α3 in interstitial lung disease and nephrotic syndrome, Hum. Mol. Genet. 24 (2015) 3679–3688. doi:10.1093/hmg/ddv111.
- [29] C. Has, G. Spartà, D. Kiritsi, L. Weibel, A. Moeller, V. Vega-Warner, A. Waters, Y. He, Y. Anikster, P. Esser, B.K. Straub, I. Hausser, D. Bockenhauer, B. Dekel, F. Hildebrandt, L. Bruckner-Tuderman, G.F. Laube, Integrin α3 mutations with kidney, lung, and skin disease, N. Engl. J. Med. 366 (2012) 1508–1514. doi:10.1056/NEJMoa1110813.
- [30] J.A. Kreidberg, M.J. Donovan, S.L. Goldstein, H. Rennke, K. Shepherd, R.C. Jones, R. Jaenisch, Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis, Dev. Camb. Engl. 122 (1996) 3537–3547.

- [31] C.M. DiPersio, K.M. Hodivala-Dilke, R. Jaenisch, J.A. Kreidberg, R.O. Hynes, alpha3beta1 Integrin is required for normal development of the epidermal basement membrane, J. Cell Biol. 137 (1997) 729–742.
- [32] C. Margadant, K. Raymond, M. Kreft, N. Sachs, H. Janssen, A. Sonnenberg, Integrin α3β1 inhibits directional migration and wound re-epithelialization in the skin, J. Cell Sci. 122 (2009) 278–288. doi:10.1242/jcs.029108.
- [33] Y.K. Hayashi, F.L. Chou, E. Engvall, M. Ogawa, C. Matsuda, S. Hirabayashi, K. Yokochi, B.L. Ziober, R.H. Kramer, S.J. Kaufman, E. Ozawa, Y. Goto, I. Nonaka, T. Tsukahara, J.Z. Wang, E.P. Hoffman, K. Arahata, Mutations in the integrin alpha7 gene cause congenital myopathy, Nat. Genet. 19 (1998) 94–97. doi:10.1038/ng0598-94.
- [34] U. Mayer, G. Saher, R. Fässler, A. Bornemann, F. Echtermeyer, H. von der Mark, N. Miosge, E. Pöschl, K. von der Mark, Absence of integrin alpha 7 causes a novel form of muscular dystrophy, Nat. Genet. 17 (1997) 318–323. doi:10.1038/ng1197-318.
- [35] E. Georges-Labouesse, M. Mark, N. Messaddeq, A. Gansmüller, Essential role of alpha 6 integrins in cortical and retinal lamination, Curr. Biol. CB. 8 (1998) 983–986.
- [36] R. Fässler, M. Meyer, Consequences of lack of beta 1 integrin gene expression in mice, Genes Dev. 9 (1995) 1896–1908.
- [37] C.S. Chen, J.L. Alonso, E. Ostuni, G.M. Whitesides, D.E. Ingber, Cell shape provides global control of focal adhesion assembly, Biochem. Biophys. Res. Commun. 307 (2003) 355–361.
- [38] L. Borradori, A. Sonnenberg, Structure and function of hemidesmosomes: more than simple adhesion complexes, J. Invest. Dermatol. 112 (1999) 411–418. doi:10.1046/j.1523-1747.1999.00546.x.
- [39] S.H.M. Litjens, J.M. de Pereda, A. Sonnenberg, Current insights into the formation and breakdown of hemidesmosomes, Trends Cell Biol. 16 (2006) 376–383. doi:10.1016/j.tcb.2006.05.004.
- [40] J.C. Jones, S.B. Hopkinson, L.E. Goldfinger, Structure and assembly of hemidesmosomes, BioEssays News Rev. Mol. Cell. Dev. Biol. 20 (1998) 488–494. doi:10.1002/(SICI)1521-1878(199806)20:6<488::AID-BIES7>3.0.CO:2-I.
- [41] G. Walko, M.J. Castañón, G. Wiche, Molecular architecture and function of the hemidesmosome, Cell Tissue Res. (2015). doi:10.1007/s00441-015-2216-6.
- [42] K. Seltmann, F. Cheng, G. Wiche, J.E. Eriksson, T.M. Magin, Keratins Stabilize Hemidesmosomes through Regulation of β4-Integrin Turnover, J. Invest. Dermatol. 135 (2015) 1609–1620. doi:10.1038/jid.2015.46.
- [43] S.-O. Yoon, S. Shin, A.M. Mercurio, Hypoxia stimulates carcinoma invasion by stabilizing microtubules and promoting the Rab11 trafficking of the alpha6beta4 integrin, Cancer Res. 65 (2005) 2761–2769. doi:10.1158/0008-5472.CAN-04-4122.
- [44] P. Rousselle, K. Beck, Laminin 332 processing impacts cellular behavior, Cell Adhes. Migr. 7 (2013) 122–134. doi:10.4161/cam.23132.
- [45] M.E. Werner, F. Chen, J.V. Moyano, F. Yehiely, J.C.R. Jones, V.L. Cryns, Caspase proteolysis of the integrin beta4 subunit disrupts hemidesmosome assembly, promotes apoptosis, and inhibits cell migration, J. Biol. Chem. 282 (2007) 5560–5569. doi:10.1074/jbc.M603669200.
- [46] F.G. Giancotti, M.A. Stepp, S. Suzuki, E. Engvall, E. Ruoslahti, Proteolytic processing of endogenous and recombinant beta 4 integrin subunit, J. Cell Biol. 118 (1992) 951–959.
- [47] C. Margadant, E. Frijns, K. Wilhelmsen, A. Sonnenberg, Regulation of hemidesmosome disassembly by growth factor receptors, Curr. Opin. Cell Biol. 20 (2008) 589–596. doi:10.1016/j. ceb.2008.05.001.
- [48] E. Frijns, N. Sachs, M. Kreft, K. Wilhelmsen, A. Sonnenberg, EGF-induced MAPK signaling inhibits hemidesmosome formation through phosphorylation of the integrin {beta}4, J. Biol. Chem. 285 (2010) 37650–37662. doi:10.1074/jbc.M110.138818.

- [49] E. Frijns, I. Kuikman, S. Litjens, M. Raspe, K. Jalink, M. Ports, K. Wilhelmsen, A. Sonnenberg, Phosphorylation of threonine 1736 in the C-terminal tail of integrin β4 contributes to hemidesmosome disassembly, Mol. Biol. Cell. 23 (2012) 1475–1485. doi:10.1091/mbc.E11-11-0957.
- [50] E.C. Germain, T.M. Santos, I. Rabinovitz, Phosphorylation of a novel site on the {beta}4 integrin at the trailing edge of migrating cells promotes hemidesmosome disassembly, Mol. Biol. Cell. 20 (2009) 56–67. doi:10.1091/mbc.E08-06-0646.
- [51] J.-E. Bouameur, Y. Schneider, N. Begré, R.P. Hobbs, P. Lingasamy, L. Fontao, K.J. Green, B. Favre, L. Borradori, Phosphorylation of serine 4,642 in the C-terminus of plectin by MNK2 and PKA modulates its interaction with intermediate filaments, J. Cell Sci. 126 (2013) 4195–4207. doi:10.1242/jcs.127779.
- [52] I. Rabinovitz, L. Tsomo, A.M. Mercurio, Protein kinase C-alpha phosphorylation of specific serines in the connecting segment of the beta 4 integrin regulates the dynamics of type II hemidesmosomes, Mol. Cell. Biol. 24 (2004) 4351–4360.
- [53] I. Rabinovitz, A.M. Mercurio, The integrin alpha6beta4 functions in carcinoma cell migration on laminin-1 by mediating the formation and stabilization of actin-containing motility structures, J. Cell Biol. 139 (1997) 1873–1884.
- [54] I. Rabinovitz, A. Toker, A.M. Mercurio, Protein kinase C-dependent mobilization of the alpha6beta4 integrin from hemidesmosomes and its association with actin-rich cell protrusions drive the chemotactic migration of carcinoma cells, J. Cell Biol. 146 (1999) 1147–1160.
- [55] R.O. Hynes, Integrins: bidirectional, allosteric signaling machines, Cell. 110 (2002) 673–687.
- [56] C. Kim, F. Ye, M.H. Ginsberg, Regulation of integrin activation, Annu. Rev. Cell Dev. Biol. 27 (2011) 321–345. doi:10.1146/annurev-cellbio-100109-104104.
- [57] F. Ye, A.K. Snider, M.H. Ginsberg, Talin and kindlin: the one-two punch in integrin activation, Front. Med. 8 (2014) 6–16. doi:10.1007/s11684-014-0317-3.
- [58] K.R. Legate, S.A. Wickström, R. Fässler, Genetic and cell biological analysis of integrin outside-in signaling, Genes Dev. 23 (2009) 397–418. doi:10.1101/gad.1758709.
- [59] K.R. Legate, R. Fässler, Mechanisms that regulate adaptor binding to beta-integrin cytoplasmic tails, J. Cell Sci. 122 (2009) 187–198. doi:10.1242/jcs.041624.
- [60] E.M. Morse, N.N. Brahme, D.A. Calderwood, Integrin cytoplasmic tail interactions, Biochemistry (Mosc.). 53 (2014) 810–820. doi:10.1021/bi401596q.
- [61] S. Liu, D.A. Calderwood, M.H. Ginsberg, Integrin cytoplasmic domain-binding proteins, J. Cell Sci. 113 (Pt 20) (2000) 3563–3571.
- [62] S.K. Mitra, D.D. Schlaepfer, Integrin-regulated FAK-Src signaling in normal and cancer cells, Curr. Opin. Cell Biol. 18 (2006) 516–523. doi:10.1016/j.ceb.2006.08.011.
- [63] C.S. Stipp, Laminin-binding integrins and their tetraspanin partners as potential antimetastatic targets, Expert Rev. Mol. Med. 12 (2010). doi:10.1017/S1462399409001355.
- [64] E.A. Lipscomb, A.M. Mercurio, Mobilization and activation of a signaling competent alpha6beta4integrin underlies its contribution to carcinoma progression, Cancer Metastasis Rev. 24 (2005) 413–423. doi:10.1007/s10555-005-5133-4.
- [65] F. Mainiero, A. Pepe, M. Yeon, Y. Ren, F.G. Giancotti, The intracellular functions of alpha6beta4 integrin are regulated by EGF, J. Cell Biol. 134 (1996) 241–253.
- [66] C. Chao, M.M. Lotz, A.C. Clarke, A.M. Mercurio, A function for the integrin alpha6beta4 in the invasive properties of colorectal carcinoma cells, Cancer Res. 56 (1996) 4811–4819.
- [67] Y.H. Soung, H.J. Gil, J.L. Clifford, J. Chung, Role of α6β4 integrin in cell motility, invasion and metastasis of mammary tumors, Curr. Protein Pept. Sci. 12 (2011) 23–29.
- [68] K. Wilhelmsen, S.H.M. Litjens, A. Sonnenberg, Multiple Functions of the Integrin α6β4 in Epidermal Homeostasis and Tumorigenesis, Mol. Cell. Biol. 26 (2006) 2877–2886. doi:10.1128/ MCB.26.8.2877-2886.2006.

- [69] M. Dans, L. Gagnoux-Palacios, P. Blaikie, S. Klein, A. Mariotti, F.G. Giancotti, Tyrosine phosphorylation of the beta 4 integrin cytoplasmic domain mediates Shc signaling to extracellular signal-regulated kinase and antagonizes formation of hemidesmosomes, J. Biol. Chem. 276 (2001) 1494–1502. doi:10.1074/jbc.M008663200.
- [70] L.M. Shaw, Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion, Mol. Cell. Biol. 21 (2001) 5082–5093. doi:10.1128/MCB.21.15.5082-5093.2001.
- [71] A. Bertotti, P.M. Comoglio, L. Trusolino, Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth, J. Cell Biol. 175 (2006) 993–1003. doi:10.1083/jcb.200605114.
- [72] M.E. Hemler, Tetraspanin functions and associated microdomains, Nat. Rev. Mol. Cell Biol. 6 (2005) 801–811. doi:10.1038/nrm1736.
- [73] H.W. Smith, C.J. Marshall, Regulation of cell signalling by uPAR, Nat. Rev. Mol. Cell Biol. 11 (2010) 23–36. doi:10.1038/nrm2821.
- [74] W. Guo, F.G. Giancotti, Integrin signalling during tumour progression, Nat. Rev. Mol. Cell Biol. 5 (2004) 816–826. doi:10.1038/nrm1490.
- [75] M.P. Marinkovich, Tumour microenvironment: laminin 332 in squamous-cell carcinoma, Nat. Rev. Cancer. 7 (2007) 370–380. doi:10.1038/nrc2089.
- [76] N. Pouliot, N. Kusuma, Laminin-511: a multi-functional adhesion protein regulating cell migration, tumor invasion and metastasis, Cell Adhes. Migr. 7 (2013) 142–149. doi:10.4161/cam.22125.
- [77] J. Jourquin, M. Tripathi, C. Guess, V. Quaranta, Laminins and Cancer Progression, in: R. Zent, A. Pozzi (Eds.), Cell-Extracell. Matrix Interact. Cancer, Springer New York, 2010: pp. 87–109. http://link.springer.com/chapter/10.1007/978-1-4419-0814-8. 5 (accessed February 19, 2016).
- [78] L. Seguin, J.S. Desgrosellier, S.M. Weis, D.A. Cheresh, Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance, Trends Cell Biol. 25 (2015) 234–240. doi:10.1016/j. tcb.2014.12.006.
- [79] S. Subbaram, C.M. Dipersio, Integrin α3β1 as a breast cancer target, Expert Opin. Ther. Targets. 15 (2011) 1197–1210. doi:10.1517/14728222.2011.609557.
- [80] J.S. Desgrosellier, D.A. Cheresh, Integrins in cancer: biological implications and therapeutic opportunities, Nat. Rev. Cancer. 10 (2010) 9–22. doi:10.1038/nrc2748.
- [81] S. Cabodi, M. del Pilar Camacho-Leal, P. Di Stefano, P. Defilippi, Integrin signalling adaptors: not only figurants in the cancer story, Nat. Rev. Cancer. 10 (2010) 858–870. doi:10.1038/nrc2967.
- [82] Y. Su, X.-Q. Guan, F.-Q. Liu, Y.-L. Wang, The effects of MIBG on the invasive properties of HepG2 hepatocellular carcinoma cells, Int. J. Mol. Med. 34 (2014) 842–848. doi:10.3892/ijmm.2014.1819.
- [83] I.C. Sroka, T.A. Anderson, K.M. McDaniel, R.B. Nagle, M.B. Gretzer, A.E. Cress, The laminin binding integrin alpha6beta1 in prostate cancer perineural invasion, J. Cell. Physiol. 224 (2010) 283–288. doi:10.1002/jcp.22149.
- [84] D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation, Cell. 144 (2011) 646–674. doi:10.1016/j.cell.2011.02.013.
- [85] D.S. Missan, S.V. Chittur, C.M. DiPersio, Regulation of fibulin-2 gene expression by integrin α3β1 contributes to the invasive phenotype of transformed keratinocytes, J. Invest. Dermatol. 134 (2014) 2418–2427. doi:10.1038/jid.2014.166.
- [86] K. Schramm, K. Krause, A. Bittroff-Leben, P. Goldin-Lang, E. Thiel, E.D. Kreuser, Activated K-ras is involved in regulation of integrin expression in human colon carcinoma cells, Int. J. Cancer J. Int. Cancer. 87 (2000) 155–164.
- [87] P.G. Natali, M.R. Nicotra, A. Bartolazzi, R. Cavaliere, A. Bigotti, Integrin expression in cutaneous malignant melanoma: association of the alpha 3/beta 1 heterodimer with tumor progression, Int. J. Cancer J. Int. Cancer. 54 (1993) 68–72.

- [88] D. Schumacher, G. Schaumburg-Lever, Ultrastructural localization of alpha-3 integrin subunit in malignant melanoma and adjacent epidermis, J. Cutan. Pathol. 26 (1999) 321–326.
- [89] N. Sachs, P. Secades, L. van Hulst, M. Kreft, J.-Y. Song, A. Sonnenberg, Loss of integrin α3 prevents skin tumor formation by promoting epidermal turnover and depletion of slow-cycling cells, Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 21468–21473. doi:10.1073/pnas.1204614110.
- [90] R.G. da Silva, B. Tavora, S.D. Robinson, L.E. Reynolds, C. Szekeres, J. Lamar, S. Batista, V. Kostourou, M.A. Germain, A.R. Reynolds, D.T. Jones, A.R. Watson, J.L. Jones, A. Harris, I.R. Hart, M.L. Iruela-Arispe, C.M. Dipersio, J.A. Kreidberg, K.M. Hodivala-Dilke, Endothelial alpha3beta1-integrin represses pathological angiogenesis and sustains endothelial-VEGF, Am. J. Pathol. 177 (2010) 1534–1548. doi:10.2353/ajpath.2010.100043.
- [91] W. Xiao, N. Yao, L. Peng, R. Liu, K.S. Lam, Near-infrared optical imaging in glioblastoma xenograft with ligand-targeting alpha 3 integrin, Eur. J. Nucl. Med. Mol. Imaging. 36 (2009) 94–103. doi:10.1007/s00259-008-0920-0.
- [92] P. Zhou, S. Erfani, Z. Liu, C. Jia, Y. Chen, B. Xu, X. Deng, J.E. Alfaro, L. Chen, D. Napier, M. Lu, J.-A. Huang, C. Liu, O. Thibault, R. Segal, B.P. Zhou, N. Kyprianou, C. Horbinski, X.H. Yang, CD151-α3β1 integrin complexes are prognostic markers of glioblastoma and cooperate with EGFR to drive tumor cell motility and invasion, Oncotarget. (2015).
- [93] T. Kawataki, T. Yamane, H. Naganuma, P. Rousselle, I. Andurén, K. Tryggvason, M. Patarroyo, Laminin isoforms and their integrin receptors in glioma cell migration and invasiveness: Evidence for a role of alpha5-laminin(s) and alpha3beta1 integrin, Exp. Cell Res. 313 (2007) 3819–3831. doi:10.1016/j.yexcr.2007.07.038.
- [94] M. Nakada, E. Nambu, N. Furuyama, Y. Yoshida, T. Takino, Y. Hayashi, H. Sato, Y. Sai, T. Tsuji, K.–. Miyamoto, A. Hirao, J.–. Hamada, Integrin α3 is overexpressed in glioma stem-like cells and promotes invasion, Br. J. Cancer. 108 (2013) 2516–2524. doi:10.1038/bjc.2013.218.
- [95] J. Chen, X. Xu, H. Wang, Expression of integrin-alpha(3) mRNA in meningiomas and its correlation with proliferation and invasion, J. Huazhong Univ. Sci. Technol. Med. Sci. Hua Zhong Ke Ji Xue Xue Bao Yi Xue Ying Wen Ban Huazhong Keji Daxue Xuebao Yixue Yingdewen Ban. 29 (2009) 94–96. doi:10.1007/s11596-009-0120-6.
- [96] S. Ghosh, J. Koblinski, J. Johnson, Y. Liu, A. Ericsson, J.W. Davis, Z. Shi, M.J. Ravosa, S. Crawford, S. Frazier, M.S. Stack, Urinary-type plasminogen activator receptor/alpha 3 beta 1 integrin signaling, altered gene expression, and oral tumor progression, Mol. Cancer Res. MCR. 8 (2010) 145–158. doi:10.1158/1541-7786.MCR-09-0045.
- [97] M. Shinohara, S. Nakamura, M. Sasaki, S. Kurahara, T. Ikebe, T. Harada, K. Shirasuna, Expression of integrins in squamous cell carcinoma of the oral cavity. Correlations with tumor invasion and metastasis, Am. J. Clin. Pathol. 111 (1999) 75–88.
- [98] M. Nagata, H. Fujita, H. Ida, H. Hoshina, T. Inoue, Y. Seki, M. Ohnishi, T. Ohyama, S. Shingaki, M. Kaji, T. Saku, R. Takagi, Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis, Int. J. Cancer J. Int. Cancer. 106 (2003) 683–689. doi:10.1002/ijc.11283.
- [99] A. Kurokawa, M. Nagata, N. Kitamura, A.A. Noman, M. Ohnishi, T. Ohyama, T. Kobayashi, S. Shingaki, R. Takagi, Oral, Maxillofacial Pathology, and Surgery Group, Diagnostic value of integrin alpha3, beta4, and beta5 gene expression levels for the clinical outcome of tongue squamous cell carcinoma, Cancer. 112 (2008) 1272–1281. doi:10.1002/cncr.23295.
- [100] H.M. Romanska, P. Potemski, S.I. Collins, H. Williams, S. Parmar, F. Berditchevski, Loss of CD151/ Tspan24 from the complex with integrin $\alpha 3\beta 1$ in invasive front of the tumour is a negative predictor of disease-free survival in oral squamous cell carcinoma, Oral Oncol. 49 (2013) 224–229. doi:10.1016/j.oraloncology.2012.09.013.

- [101] M. Nagata, A.A. Noman, K. Suzuki, H. Kurita, M. Ohnishi, T. Ohyama, N. Kitamura, T. Kobayashi, K. Uematsu, K. Takahashi, N. Kodama, T. Kawase, H. Hoshina, N. Ikeda, S. Shingaki, R. Takagi, ITGA3 and ITGB4 expression biomarkers estimate the risks of locoregional and hematogenous dissemination of oral squamous cell carcinoma, BMC Cancer. 13 (2013) 410. doi:10.1186/1471-2407-13-410.
- [102] J. Peixoto da-Silva, S. Lourenço, M. Nico, F.H. Silva, M.T. Martins, A. Costa-Neves, Expression of laminin-5 and integrins in actinic cheilitis and superficially invasive squamous cell carcinomas of the lip, Pathol. Res. Pract. 208 (2012) 598–603. doi:10.1016/j.prp.2012.07.004.
- [103] T. Ohara, S. Kawashiri, A. Tanaka, N. Noguchi, H. Kitahara, A. Okamune, K. Kato, T. Hase, H. Nakaya, K. Yoshizawa, Integrin expression levels correlate with invasion, metastasis and prognosis of oral squamous cell carcinoma, Pathol. Oncol. Res. POR. 15 (2009) 429–436. doi:10.1007/s12253-008-9142-9.
- [104] Y. Zhao, X. Liu, L. Zhong, M. He, S. Chen, T. Wang, S. Ma, The combined use of miRNAs and mRNAs as biomarkers for the diagnosis of papillary thyroid carcinoma, Int. J. Mol. Med. 36 (2015) 1097–1103. doi:10.3892/ijmm.2015.2305.
- [105] O.H. Dyce, A.F. Ziober, R.S. Weber, K. Miyazaki, S.S. Khariwala, M. Feldman, B.L. Ziober, Integrins in head and neck squamous cell carcinoma invasion, The Laryngoscope. 112 (2002) 2025–2032. doi:10.1097/00005537-200211000-00021.
- [106] M.C. Boelens, A. van den Berg, I. Vogelzang, J. Wesseling, D.S. Postma, W. Timens, H.J.M. Groen, Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus, J. Clin. Pathol. 60 (2007) 608–614. doi:10.1136/jcp.2005.031443.
- [107] G. Alì, N. Borrelli, G. Riccardo, A. Proietti, S. Pelliccioni, C. Niccoli, L. Boldrini, M. Lucchi, A. Mussi, G. Fontanini, Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia, J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer. 8 (2013) 1389–1395. doi:10.1097/JTO.0b013e3182a59f45.
- [108] T. Yoshimasu, T. Sakurai, S. Oura, I. Hirai, H. Tanino, Y. Kokawa, Y. Naito, Y. Okamura, I. Ota, N. Tani, N. Matsuura, Increased expression of integrin alpha3beta1 in highly brain metastatic subclone of a human non-small cell lung cancer cell line, Cancer Sci. 95 (2004) 142–148.
- [109] H. Wang, W. Fu, J.H. Im, Z. Zhou, S.A. Santoro, V. Iyer, C.M. DiPersio, Q.-C. Yu, V. Quaranta, A. Al-Mehdi, R.J. Muschel, Tumor cell alpha3beta1 integrin and vascular laminin-5 mediate pulmonary arrest and metastasis, J. Cell Biol. 164 (2004) 935–941. doi:10.1083/jcb.200309112.
- [110] C.S. Boosani, A.P. Mannam, D. Cosgrove, R. Silva, K.M. Hodivala-Dilke, V.G. Keshamouni, A. Sudhakar, Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis, Blood. 110 (2007) 1168–1177. doi:10.1182/blood-2007-01-066282.
- [111] M. Adachi, T. Taki, C. Huang, M. Higashiyama, O. Doi, T. Tsuji, M. Miyake, Reduced integrin alpha3 expression as a factor of poor prognosis of patients with adenocarcinoma of the lung, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 16 (1998) 1060–1067.
- [112] K. Mitchell, K.B. Svenson, W.M. Longmate, K. Gkirtzimanaki, R. Sadej, X. Wang, J. Zhao, A.G. Eliopoulos, F. Berditchevski, C.M. Dipersio, Suppression of integrin alpha3beta1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and crosstalk to endothelial cells, Cancer Res. 70 (2010) 6359–6367. doi:10.1158/0008-5472.CAN-09-4283.
- [113] T. Shirakihara, T. Kawasaki, A. Fukagawa, K. Semba, R. Sakai, K. Miyazono, K. Miyazawa, M. Saitoh, Identification of integrin α3 as a molecular marker of cells undergoing epithelial-mesenchymal transition and of cancer cells with aggressive phenotypes, Cancer Sci. 104 (2013) 1189–1197. doi:10.1111/cas.12220.
- [114] V. Novitskaya, H. Romanska, R. Kordek, P. Potemski, R. Kusińska, M. Parsons, E. Odintsova, F. Berditchevski, Integrin α3β1-CD151 complex regulates dimerization of ErbB2 via RhoA, Oncogene. 33 (2014) 2779–2789. doi:10.1038/onc.2013.231.

- [115] A. Aggarwal, R.N. Al-Rohil, A. Batra, P.J. Feustel, D.M. Jones, C.M. DiPersio, Expression of integrin $\alpha 3\beta 1$ and cyclooxygenase-2 (COX2) are positively correlated in human breast cancer, BMC Cancer. 14 (2014) 459. doi:10.1186/1471-2407-14-459.
- [116] S. Cagnet, M.M. Faraldo, M. Kreft, A. Sonnenberg, K. Raymond, M.A. Glukhova, Signaling events mediated by $\alpha 3\beta 1$ integrin are essential for mammary tumorigenesis, Oncogene. 33 (2014) 4286–4295. doi:10.1038/onc.2013.391.
- [117] B. Zhou, K.N. Gibson-Corley, M.E. Herndon, Y. Sun, E. Gustafson-Wagner, M. Teoh-Fitzgerald, F.E. Domann, M.D. Henry, C.S. Stipp, Integrin α3β1 can function to promote spontaneous metastasis and lung colonization of invasive breast carcinoma, Mol. Cancer Res. MCR. 12 (2014) 143–154. doi:10.1158/1541-7786.MCR-13-0184.
- [118] H.M. Romanska, P. Potemski, M. Krakowska, M. Mieszkowska, S. Chaudhri, R. Kordek, R. Kubiak, V. Speirs, A.M. Hanby, R. Sadej, F. Berditchevski, Lack of CD151/integrin α3β1 complex is predictive of poor outcome in node-negative lobular breast carcinoma: opposing roles of CD151 in invasive lobular and ductal breast cancers, Br. J. Cancer. (2015). doi:10.1038/bjc.2015.344.
- [119] M. Morini, M. Mottolese, N. Ferrari, F. Ghiorzo, S. Buglioni, R. Mortarini, D.M. Noonan, P.G. Natali, A. Albini, The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity, Int. I. Cancer I. Int. Cancer. 87 (2000) 336–342.
- [120] G.P. Gui, C.A. Wells, P.D. Browne, P. Yeomans, S. Jordan, J.R. Puddefoot, G.P. Vinson, R. Carpenter, Integrin expression in primary breast cancer and its relation to axillary nodal status, Surgery. 117 (1995) 102–108.
- [121] G.P. Gui, C.A. Wells, P. Yeomans, S.E. Jordan, G.P. Vinson, R. Carpenter, Integrin expression in breast cancer cytology: a novel predictor of axillary metastasis, Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 22 (1996) 254–258.
- [122] M. Pignatelli, A.M. Hanby, G.W. Stamp, Low expression of beta 1, alpha 2 and alpha 3 subunits of VLA integrins in malignant mammary tumours, J. Pathol. 165 (1991) 25–32. doi:10.1002/ path.1711650106.
- [123] J. Pontes-Júnior, S.T. Reis, L.C.N. de Oliveira, A.C. Sant'anna, M.F. Dall'oglio, A.A. Antunes, L.A. Ribeiro-Filho, P.A. Carvalho, J. Cury, M. Srougi, K.R.M. Leite, Association between integrin expression and prognosis in localized prostate cancer, The Prostate. 70 (2010) 1189–1195. doi:10.1002/pros.21153.
- [124] S. Dedhar, R. Saulnier, R. Nagle, C.M. Overall, Specific alterations in the expression of alpha 3 beta 1 and alpha 6 beta 4 integrins in highly invasive and metastatic variants of human prostate carcinoma cells selected by in vitro invasion through reconstituted basement membrane, Clin. Exp. Metastasis. 11 (1993) 391–400.
- [125] A. Timmer, J.W. Oosterhuis, H. Schraffordt Koops, D.T. Sleijfer, B.G. Szabo, W. Timens, The tumor microenvironment: possible role of integrins and the extracellular matrix in tumor biological behavior of intratubular germ cell neoplasia and testicular seminomas, Am. J. Pathol. 144 (1994) 1035–1044.
- [126] S. Miyamoto, A. Maruyama, K. Okugawa, K. Akazawa, H. Baba, Y. Maehara, E. Mekada, Loss of motility-related protein 1 (MRP1/CD9) and integrin alpha3 expression in endometrial cancers, Cancer. 92 (2001) 542–548.
- [127] M. Schmelz, A.E. Cress, K.M. Scott, F. Bürgery, H. Cui, K. Sallam, K.M. McDaniel, B.L. Dalkin, R.B. Nagle, Different Phenotypes in Human Prostate Cancer: α6 or α3 Integrin in Cell-extracellular Adhesion Sites, Neoplasia N. Y. N. 4 (2002) 243–254.
- [128] L.A. Baldwin, J.T. Hoff, J. Lefringhouse, M. Zhang, C. Jia, Z. Liu, S. Erfani, H. Jin, M. Xu, Q.-B. She, J.R. van Nagell, C. Wang, L. Chen, R. Plattner, D.M. Kaetzel, J. Luo, M. Lu, D. West, C. Liu, F.R. Ueland, R. Drapkin, B.P. Zhou, X.H. Yang, CD151-α3β1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling, Oncotarget. 5 (2014) 12203–12217.

- [129] A. Varzavand, J.M. Drake, R.U. Svensson, M.E. Herndon, B. Zhou, M.D. Henry, C.S. Stipp, Integrin α3β1 regulates tumor cell responses to stromal cells and can function to suppress prostate cancer metastatic colonization, Clin. Exp. Metastasis. 30 (2013) 541–552. doi:10.1007/s10585-012-9558-1.
- [130] T.D. Palmer, C.H. Martínez, C. Vasquez, K.E. Hebron, C. Jones-Paris, S.A. Arnold, S.M. Chan, V. Chalasani, J.A. Gomez-Lemus, A.K. Williams, J.L. Chin, G.A. Giannico, T. Ketova, J.D. Lewis, A. Zijlstra, Integrin-free tetraspanin CD151 can inhibit tumor cell motility upon clustering and is a clinical indicator of prostate cancer progression, Cancer Res. 74 (2014) 173–187. doi:10.1158/0008-5472. CAN-13-0275.
- [131] M.M. Linhares, R.J. Affonso, L. de S. Viana, S.R.M. Silva, M.V.A. Denadai, S.R.C. de Toledo, D. Matos, Genetic and Immunohistochemical Expression of Integrins ITGAV, ITGA6, and ITGA3 As Prognostic Factor for Colorectal Cancer: Models for Global and Disease-Free Survival, PloS One. 10 (2015) e0144333. doi:10.1371/journal.pone.0144333.
- [132] H. Ura, R. Denno, K. Hirata, K. Yamaguchi, T. Yasoshima, Separate functions of alpha2beta1 and alpha3beta1 integrins in the metastatic process of human gastric carcinoma, Surg. Today. 28 (1998) 1001–1006.
- [133] H. Takatsuki, S. Komatsu, R. Sano, Y. Takada, T. Tsuji, Adhesion of gastric carcinoma cells to peritoneum mediated by alpha3beta1 integrin (VLA-3), Cancer Res. 64 (2004) 6065–6070. doi:10.1158/0008-5472.CAN-04-0321.
- [134] M.V. Denadai, L.S. Viana, R.J. Affonso, S.R. Silva, I.D. Oliveira, S.R. Toledo, D. Matos, Expression of integrin genes and proteins in progression and dissemination of colorectal adenocarcinoma, BMC Clin. Pathol. 13 (2013) 16. doi:10.1186/1472-6890-13-16.
- [135] H. Hashida, A. Takabayashi, T. Tokuhara, T. Taki, K. Kondo, N. Kohno, Y. Yamaoka, M. Miyake, Integrin alpha3 expression as a prognostic factor in colon cancer: association with MRP-1/CD9 and KAI1/CD82, Int. J. Cancer J. Int. Cancer. 97 (2002) 518–525.
- [136] H. Hashida, A. Takabayashi, M. Adachi, T. Imai, K. Kondo, N. Kohno, Y. Yamaoka, M. Miyake, The novel monoclonal antibody MH8-4 inhibiting cell motility recognizes integrin alpha 3: inverse of its expression withmetastases in colon cancer, Int. J. Oncol. 18 (2001) 89–95.
- [137] G.-H. Zhu, C. Huang, Z.-J. Qiu, J. Liu, Z.-H. Zhang, N. Zhao, Z.-Z. Feng, X.-H. Lv, Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma, Dig. Dis. Sci. 56 (2011) 1090–1098. doi:10.1007/s10620-010-1416-x.
- [138] G. Giannelli, E. Fransvea, F. Marinosci, C. Bergamini, S. Colucci, O. Schiraldi, S. Antonaci, Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin, Am. J. Pathol. 161 (2002) 183–193.
- [139] C. Li, Z. Yang, Y. Du, H. Tang, J. Chen, D. Hu, Z. Fan, BCMab1, a monoclonal antibody against aberrantly glycosylated integrin α3β1, has potent antitumor activity of bladder cancer in vivo, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 20 (2014) 4001–4013. doi:10.1158/1078-0432. CCR-13-3397.
- [140] H.M. Behnsawy, H. Miyake, M.A. Abdalla, M.A. Sayed, A.E.-F.I. Ahmed, M. Fujisawa, Expression of integrin proteins in non-muscle-invasive bladder cancer: significance of intravesical recurrence after transurethral resection, BJU Int. 107 (2011) 240–246. doi:10.1111/j.1464-410X.2010.09534.x.
- [141] M. Bockhorn, S. Roberge, C. Sousa, R.K. Jain, L.L. Munn, Differential gene expression in metastasizing cells shed from kidney tumors, Cancer Res. 64 (2004) 2469–2473.
- [142] F. de Nigris, C. Botti, R. Rossiello, E. Crimi, V. Sica, C. Napoli, Cooperation between Myc and YY1 provides novel silencing transcriptional targets of alpha3beta1-integrin in tumour cells, Oncogene. 26 (2007) 382–394. doi:10.1038/sj.onc.1209804.
- [143] A.K. Fournier, L.E. Campbell, P. Castagnino, W.F. Liu, B.M. Chung, V.M. Weaver, C.S. Chen, R.K. Assoian, Rac-dependent cyclin D1 gene expression regulated by cadherin- and integrin-mediated adhesion, J. Cell Sci. 121 (2008) 226–233. doi:10.1242/jcs.017012.

- [144] M. Gonzales, K. Haan, S.E. Baker, M. Fitchmun, I. Todorov, S. Weitzman, J.C. Jones, A cell signal pathway involving laminin-5, alpha3beta1 integrin, and mitogen-activated protein kinase can regulate epithelial cell proliferation, Mol. Biol. Cell. 10 (1999) 259–270.
- [145] C. Bergamini, C. Sgarra, P. Trerotoli, L. Lupo, A. Azzariti, S. Antonaci, G. Giannelli, Laminin-5 stimulates hepatocellular carcinoma growth through a different function of alpha6beta4 and alpha3beta1 integrins, Hepatol. Baltim. Md. 46 (2007) 1801–1809. doi:10.1002/hep.21936.
- [146] N. Ahmed, C. Riley, G. Rice, M. Quinn, Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment, Clin. Exp. Metastasis. 22 (2005) 391–402. doi:10.1007/s10585-005-1262-y.
- [147] H.J. Yoon, Y.-R. Cho, J.-H. Joo, D.-W. Seo, Knockdown of integrin α3β1 expression induces proliferation and migration of non-small cell lung cancer cells, Oncol. Rep. 29 (2013) 662–668. doi:10.3892/or.2012.2169.
- [148] A. Manohar, S.G. Shome, J. Lamar, L. Stirling, V. Iyer, K. Pumiglia, C.M. DiPersio, Alpha 3 beta 1 integrin promotes keratinocyte cell survival through activation of a MEK/ERK signaling pathway, J. Cell Sci. 117 (2004) 4043–4054. doi:10.1242/jcs.01277.
- [149] A. Steglich, A. Vehlow, I. Eke, N. Cordes, α integrin targeting for radiosensitization of threedimensionally grown human head and neck squamous cell carcinoma cells, Cancer Lett. 357 (2015) 542–548. doi:10.1016/j.canlet.2014.12.009.
- [150] K. Mitchell, C. Szekeres, V. Milano, K.B. Svenson, M. Nilsen-Hamilton, J.A. Kreidberg, C.M. DiPersio, Alpha3beta1 integrin in epidermis promotes wound angiogenesis and keratinocyte-to-endothelial-cell crosstalk through the induction of MRP3, J. Cell Sci. 122 (2009) 1778–1787. doi:10.1242/jcs.040956.
- [151] H.-J. Kim, Y.-R. Cho, S.H. Kim, D.-W. Seo, TIMP-2-derived 18-mer peptide inhibits endothelial cell proliferation and migration through cAMP/PKA-dependent mechanism, Cancer Lett. 343 (2014) 210–216. doi:10.1016/j.canlet.2013.10.037.
- [152] D.-W. Seo, H. Li, L. Guedez, P.T. Wingfield, T. Diaz, R. Salloum, B. Wei, W.G. Stetler-Stevenson, TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism, Cell. 114 (2003) 171–180.
- [153] S. Subbaram, S.P. Lyons, K.B. Svenson, S.L. Hammond, L.G. McCabe, S.V. Chittur, C.M. DiPersio, Integrin α3β1 controls mRNA splicing that determines Cox-2 mRNA stability in breast cancer cells, J. Cell Sci. 127 (2014) 1179–1189. doi:10.1242/jcs.131227.
- [154] H. le Kim, H.-S. Lee, T.H. Kim, J.-S. Lee, S.-T. Lee, S.-J. Lee, Growth-stimulatory activity of TIMP-2 is mediated through c-Src activation followed by activation of FAK, PI3-kinase/AKT, and ERK1/2 independent of MMP inhibition in lung adenocarcinoma cells, Oncotarget. 6 (2015) 42905–42922. doi:10.18632/oncotarget.5466.
- [155] N. Guo, N.S. Templeton, H. Al-Barazi, J.A. Cashel, J.M. Sipes, H.C. Krutzsch, D.D. Roberts, Thrombospondin-1 promotes alpha3beta1 integrin-mediated adhesion and neurite-like outgrowth and inhibits proliferation of small cell lung carcinoma cells, Cancer Res. 60 (2000) 457–466.
- [156] D. Ndishabandi, C. Duquette, G.E.-M. Billah, M. Reyes, M. Duquette, J. Lawler, S. Kazerounian, Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro, Discoveries. 2 (2014). doi:10.15190/d.2014.23.
- [157] R. Sadej, H. Romanska, G. Baldwin, K. Gkirtzimanaki, V. Novitskaya, A.D. Filer, Z. Krcova, R. Kusinska, J. Ehrmann, C.D. Buckley, R. Kordek, P. Potemski, A.G. Eliopoulos, E.-N. Lalani, F. Berditchevski, CD151 regulates tumorigenesis by modulating the communication between tumor cells and endothelium, Mol. Cancer Res. MCR. 7 (2009) 787–798. doi:10.1158/1541-7786.MCR-08-0574.
- [158] E.M. Pinatel, F. Orso, E. Penna, D. Cimino, A.R. Elia, P. Circosta, P. Dentelli, M.F. Brizzi, P. Provero, D. Taverna, miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions, PloS One. 9 (2014) e84859. doi:10.1371/journal.pone.0084859.

- [159] A. Kurozumi, Y. Goto, R. Matsushita, I. Fukumoto, M. Kato, R. Nishikawa, S. Sakamoto, H. Enokida, M. Nakagawa, T. Ichikawa, N. Seki, Tumor-suppressive microRNA-223 inhibits cancer cell migration and invasion by targeting ITGA3/ITGB1 signaling in prostate cancer, Cancer Sci. (2015). doi:10.1111/ cas.12842.
- [160] A. Melchiori, R. Mortarini, S. Carlone, P.C. Marchisio, A. Anichini, D.M. Noonan, A. Albini, The alpha 3 beta 1 integrin is involved in melanoma cell migration and invasion, Exp. Cell Res. 219 (1995) 233–242. doi:10.1006/excr.1995.1223.
- [161] N. Suzuki, A. Higashiguchi, Y. Hasegawa, H. Matsumoto, S. Oie, K. Orikawa, S. Ezawa, N. Susumu, K.-I. Miyashita, D. Aoki, Loss of integrin alpha3 expression associated with acquisition of invasive potential by ovarian clear cell adenocarcinoma cells, Hum. Cell. 18 (2005) 147–155.
- [162] K. Katabami, H. Mizuno, R. Sano, Y. Saito, M. Ogura, S. Itoh, T. Tsuji, Transforming growth factor-beta1 upregulates transcription of alpha3 integrin gene in hepatocellular carcinoma cells via Ets-transcription factor-binding motif in the promoter region, Clin. Exp. Metastasis. 22 (2005) 539–548. doi:10.1007/s10585-005-5260-x.
- [163] K. Zhang, R.H. Kramer, Laminin 5 deposition promotes keratinocyte motility, Exp. Cell Res. 227 (1996) 309–322. doi:10.1006/excr.1996.0280.
- [164] D.P. Choma, V. Milano, K.M. Pumiglia, C.M. DiPersio, Integrin alpha3beta1-dependent activation of FAK/Src regulates Rac1-mediated keratinocyte polarization on laminin-5, J. Invest. Dermatol. 127 (2007) 31–40. doi:10.1038/sj.jid.5700505.
- [165] A. Kwiatkowska, M. Symons, Signaling determinants of glioma cell invasion, Adv. Exp. Med. Biol. 986 (2013) 121–141. doi:10.1007/978-94-007-4719-7_7.
- [166] Y. Fukushima, T. Ohnishi, N. Arita, T. Hayakawa, K. Sekiguchi, Integrin alpha3beta1-mediated interaction with laminin-5 stimulates adhesion, migration and invasion of malignant glioma cells, Int. J. Cancer J. Int. Cancer. 76 (1998) 63–72.
- [167] R. Mahesparan, T.-A. Read, M. Lund-Johansen, K.O. Skaftnesmo, R. Bjerkvig, O. Engebraaten, Expression of extracellular matrix components in a highly infiltrative in vivo glioma model, Acta Neuropathol. (Berl.). 105 (2003) 49–57. doi:10.1007/s00401-002-0610-0.
- [168] R.C. Ireton, J. Chen, EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics, Curr. Cancer Drug Targets. 5 (2005) 149–157.
- [169] A. Makarov, I. Ylivinkka, T.A. Nyman, M. Hyytiäinen, J. Keski-Oja, Ephrin-As, Eph receptors and integrin α3 interact and colocalise at membrane protrusions of U251MG glioblastoma cells, Cell Biol. Int. 37 (2013) 1080–1088. doi:10.1002/cbin.10134.
- [170] H. Mizuno, M. Ogura, Y. Saito, W. Sekine, R. Sano, T. Gotou, T. Oku, S. Itoh, K. Katabami, T. Tsuji, Changes in adhesive and migratory characteristics of hepatocellular carcinoma (HCC) cells induced by expression of alpha3beta1 integrin, Biochim. Biophys. Acta. 1780 (2008) 564–570. doi:10.1016/j.bbagen.2007.09.007.
- [171] J. Lohi, J. Oivula, E. Kivilaakso, T. Kiviluoto, K. Fröjdman, Y. Yamada, R.E. Burgeson, I. Leivo, I. Virtanen, Basement membrane laminin-5 is deposited in colorectal adenomas and carcinomas and serves as a ligand for alpha3beta1 integrin, APMIS Acta Pathol. Microbiol. Immunol. Scand. 108 (2000) 161–172.
- [172] N. Pouliot, E.C. Nice, A.W. Burgess, Laminin-10 mediates basal and EGF-stimulated motility of human colon carcinoma cells via alpha(3)beta(1) and alpha(6)beta(4) integrins, Exp. Cell Res. 266 (2001) 1–10. doi:10.1006/excr.2001.5197.
- [173] T. Tsuji, Y. Kawada, M. Kai-Murozono, S. Komatsu, S.A. Han, K. Takeuchi, H. Mizushima, K. Miyazaki, T. Irimura, Regulation of melanoma cell migration and invasion by laminin-5 and alpha3beta1 integrin (VLA-3), Clin. Exp. Metastasis. 19 (2002) 127–134.
- [174] I.G. Yoshinaga, J. Vink, S.K. Dekker, M.C. Mihm, H.R. Byers, Role of alpha 3 beta 1 and alpha 2 beta 1 integrins in melanoma cell migration, Melanoma Res. 3 (1993) 435–441.

- [175] H.-M. Yu, D.E. Frank, J. Zhang, X. You, W.G. Carter, B.S. Knudsen, Basal prostate epithelial cells stimulate the migration of prostate cancer cells, Mol. Carcinog. 41 (2004) 85–97. doi:10.1002/ mc.20041.
- [176] H. Zhou, R.H. Kramer, Integrin engagement differentially modulates epithelial cell motility by RhoA/ROCK and PAK1, I. Biol. Chem. 280 (2005) 10624–10635. doi:10.1074/jbc.M411900200.
- [177] Y. Saito, W. Sekine, R. Sano, S. Komatsu, H. Mizuno, K. Katabami, K. Shimada, T. Oku, T. Tsuji, Potentiation of cell invasion and matrix metalloproteinase production by alpha3beta1 integrinmediated adhesion of gastric carcinoma cells to laminin-5, Clin. Exp. Metastasis. 27 (2010) 197– 205. doi:10.1007/s10585-010-9314-3.
- [178] A. Wright, Y.-H. Li, C. Zhu, The differential effect of endothelial cell factors on in vitro motility of malignant and non-malignant cells, Ann. Biomed. Eng. 36 (2008) 958–969. doi:10.1007/s10439-008-9489-9.
- [179] T. Okada, H. Okuno, Y. Mitsui, A novel in vitro assay system for transendothelial tumor cell invasion: significance of E-selectin and alpha 3 integrin in the transendothelial invasion by HT1080 fibrosarcoma cells, Clin. Exp. Metastasis. 12 (1994) 305–314.
- [180] O.V. Glinskii, F. Li, L.S. Wilson, S. Barnes, K. Rittenhouse-Olson, J.J. Barchi, K.J. Pienta, V.V. Glinsky, Endothelial integrin α3β1 stabilizes carbohydrate-mediated tumor/endothelial cell adhesion and induces macromolecular signaling complex formation at the endothelial cell membrane, Oncotarget. 5 (2014) 1382–1389. doi:10.18632/oncotarget.1837.
- [181] B.-H. Fu, Z.-Z. Wu, J. Qin, Effects of integrins on laminin chemotaxis by hepatocellular carcinoma cells, Mol. Biol. Rep. 37 (2010) 1665–1670. doi:10.1007/s11033-009-9790-1.
- [182] J. Chia, N. Kusuma, R. Anderson, B. Parker, B. Bidwell, L. Zamurs, E. Nice, N. Pouliot, Evidence for a role of tumor-derived laminin-511 in the metastatic progression of breast cancer, Am. J. Pathol. 170 (2007) 2135–2148. doi:10.2353/ajpath.2007.060709.
- [183] N. Kusuma, D. Denoyer, J.A. Eble, R.P. Redvers, B.S. Parker, R. Pelzer, R.L. Anderson, N. Pouliot, Integrin-dependent response to laminin-511 regulates breast tumor cell invasion and metastasis, Int. J. Cancer J. Int. Cancer. 130 (2012) 555–566. doi:10.1002/jjc.26018.
- [184] N.J. Tawil, V. Gowri, M. Djoneidi, J. Nip, S. Carbonetto, P. Brodt, Integrin alpha3beta1 can promote adhesion and spreading of metastatic breast carcinoma cells on the lymph node stroma, Int. J. Cancer J. Int. Cancer. 66 (1996) 703–710. doi:10.1002/(SICI)1097-0215(19960529)66:5<703::AID-IJC20>3.0.CO;2-3.
- [185] K.T. Chan, C.L. Cortesio, A. Huttenlocher, FAK alters invadopodia and focal adhesion composition and dynamics to regulate breast cancer invasion, J. Cell Biol. 185 (2009) 357–370. doi:10.1083/ jcb.200809110.
- [186] S. Liu, H. Yamashita, B. Weidow, A.M. Weaver, V. Quaranta, Laminin-332-beta1 integrin interactions negatively regulate invadopodia, J. Cell. Physiol. 223 (2010) 134–142. doi:10.1002/jcp.22018.
- [187] I. Sordat, C. Decraene, T. Silvestre, O. Petermann, C. Auffray, G. Piétu, B. Sordat, Complementary DNA arrays identify CD63 tetraspanin and alpha3 integrin chain as differentially expressed in low and high metastatic human colon carcinoma cells, Lab. Investig. J. Tech. Methods Pathol. 82 (2002) 1715–1724.
- [188] E. Gustafson-Wagner, C.S. Stipp, The CD9/CD81 tetraspanin complex and tetraspanin CD151 regulate $\alpha 3\beta 1$ integrin-dependent tumor cell behaviors by overlapping but distinct mechanisms, PloS One. 8 (2013) e61834. doi:10.1371/journal.pone.0061834.
- [189] K. Mitsuzuka, K. Handa, M. Satoh, Y. Arai, S. Hakomori, A specific microdomain ("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha3beta1 integrin with CD9, J. Biol. Chem. 280 (2005) 35545–35553. doi:10.1074/jbc.M505630200.
- [190] S.-J. Pan, S.-K. Zhan, Y.-X. Pan, W. Liu, L.-G. Bian, B. Sun, Q.-F. Sun, Tetraspanin 8-rictor-integrin α3 complex is required for glioma cell migration, Int. J. Mol. Sci. 16 (2015) 5363–5374. doi:10.3390/ijms16035363.

- [191] L.M.T. Sterk, C.A.W. Geuijen, J.G. van den Berg, N. Claessen, J.J. Weening, A. Sonnenberg, Association of the tetraspanin CD151 with the laminin-binding integrins alpha3beta1, alpha6beta1, alpha6beta4 and alpha7beta1 in cells in culture and in vivo, J. Cell Sci. 115 (2002) 1161–1173.
- [192] R.L. Yauch, F. Berditchevski, M.B. Harler, J. Reichner, M.E. Hemler, Highly stoichiometric, stable, and specific association of integrin alpha3beta1 with CD151 provides a major link to phosphatidylinositol 4-kinase, and may regulate cell migration, Mol. Biol. Cell. 9 (1998) 2751–2765.
- [193] N. Sachs, N. Claessen, J. Aten, M. Kreft, G.J.D. Teske, A. Koeman, C.J. Zuurbier, H. Janssen, A. Sonnenberg, Blood pressure influences end-stage renal disease of Cd151 knockout mice, J. Clin. Invest. 122 (2012) 348–358. doi:10.1172/JCI58878.
- [194] N.E. Winterwood, A. Varzavand, M.N. Meland, L.K. Ashman, C.S. Stipp, A critical role for tetraspanin CD151 in alpha3beta1 and alpha6beta4 integrin-dependent tumor cell functions on laminin-5, Mol. Biol. Cell. 17 (2006) 2707–2721. doi:10.1091/mbc.E05-11-1042.
- [195] S. Zevian, N.E. Winterwood, C.S. Stipp, Structure-function analysis of tetraspanin CD151 reveals distinct requirements for tumor cell behaviors mediated by α3β1 versus α6β4 integrin, J. Biol. Chem. 286 (2011) 7496–7506. doi:10.1074/jbc.M110.173583.
- [196] W. Yang, P. Li, J. Lin, H. Zuo, P. Zuo, Y. Zou, Z. Liu, CD151 promotes proliferation and migration of PC3 cells via the formation of CD151-integrin α3/α6 complex, J. Huazhong Univ. Sci. Technol. Med. Sci. Hua Zhong Ke Ji Xue Xue Bao Yi Xue Ying Wen Ban Huazhong Keji Daxue Xuebao Yixue Yingdewen Ban. 32 (2012) 383–388. doi:10.1007/s11596-012-0066-y.
- [197] L. Liu, B. He, W.M. Liu, D. Zhou, J.V. Cox, X.A. Zhang, Tetraspanin CD151 promotes cell migration by regulating integrin trafficking, J. Biol. Chem. 282 (2007) 31631–31642. doi:10.1074/jbc. M701165200.
- [198] I.-K. Hong, D.-I. Jeoung, K.-S. Ha, Y.-M. Kim, H. Lee, Tetraspanin CD151 stimulates adhesion-dependent activation of Ras, Rac, and Cdc42 by facilitating molecular association between β1 integrins and small GTPases, J. Biol. Chem. 287 (2012) 32027–32039. doi:10.1074/jbc.M111.314443.
- [199] T.M.E. Scales, A. Jayo, B. Obara, M.R. Holt, N.A. Hotchin, F. Berditchevski, M. Parsons, α3β1 integrins regulate CD151 complex assembly and membrane dynamics in carcinoma cells within 3D environments, Oncogene. 32 (2013) 3965–3979. doi:10.1038/onc.2012.415.
- [200] G. Chometon, Z.-G. Zhang, E. Rubinstein, C. Boucheix, C. Mauch, M. Aumailley, Dissociation of the complex between CD151 and laminin-binding integrins permits migration of epithelial cells, Exp. Cell Res. 312 (2006) 983–995. doi:10.1016/j.yexcr.2005.12.034.
- [201] H.M. Romanska, P. Potemski, S.I. Collins, H. Williams, S. Parmar, F. Berditchevski, Loss of CD151/ Tspan24 from the complex with integrin $\alpha 3\beta 1$ in invasive front of the tumour is a negative predictor of disease-free survival in oral squamous cell carcinoma, Oral Oncol. 49 (2013) 224–229. doi:10.1016/j.oraloncology.2012.09.013.
- [202] A. Ranjan, S.M. Bane, R.D. Kalraiya, Glycosylation of the laminin receptor (α3β1) regulates its association with tetraspanin CD151: Impact on cell spreading, motility, degradation and invasion of basement membrane by tumor cells, Exp. Cell Res. 322 (2014) 249–264. doi:10.1016/j. yexcr.2014.02.004.
- [203] H.M. Romanska, P. Potemski, R. Kusinska, J. Kopczynski, R. Sadej, R. Kordek, Expression of CD151/ Tspan24 and integrin alpha 3 complex in aid of prognostication of HER2-negative high-grade ductal carcinoma in situ, Int. I. Clin. Exp. Pathol. 8 (2015) 9471–9478.
- [204] X.H. Yang, L.M. Flores, Q. Li, P. Zhou, F. Xu, I.E. Krop, M.E. Hemler, Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists, Cancer Res. 70 (2010) 2256–2263. doi:10.1158/0008-5472.CAN-09-4032.
- [205] B. Weigelt, F.C. Geyer, R. Natrajan, M.A. Lopez-Garcia, A.S. Ahmad, K. Savage, B. Kreike, J.S. Reis-Filho, The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type, J. Pathol. 220 (2010) 45–57. doi:10.1002/path.2629.

- [206] N. Chattopadhyay, Z. Wang, L.K. Ashman, S.M. Brady-Kalnay, J.A. Kreidberg, α3β1 integrin–CD151, a component of the cadherin–catenin complex, regulates PTPµ expression and cell–cell adhesion, J. Cell Biol. 163 (2003) 1351–1362. doi:10.1083/jcb.200306067.
- [207] J.L. Johnson, N. Winterwood, K.A. DeMali, C.S. Stipp, Tetraspanin CD151 regulates RhoA activation and the dynamic stability of carcinoma cell-cell contacts, J. Cell Sci. 122 (2009) 2263–2273. doi:10.1242/jcs.045997.
- [208] S.C. Zevian, J.L. Johnson, N.E. Winterwood, K.S. Walters, M.E. Herndon, M.D. Henry, C.S. Stipp, CD151 Promotes α3β1 Integrin-Dependent Organization of Carcinoma Cell Junctions and Restrains Collective Cell Invasion, Cancer Biol. Ther. (2015) 0. doi:10.1080/15384047.2015.10953 96
- [209] S. Ghosh, J.J. Johnson, R. Sen, S. Mukhopadhyay, Y. Liu, F. Zhang, Y. Wei, H.A. Chapman, M.S. Stack, Functional relevance of urinary-type plasminogen activator receptor-alpha3beta1 integrin association in proteinase regulatory pathways, J. Biol. Chem. 281 (2006) 13021–13029. doi:10.1074/jbc.M508526200.
- [210] Z. Shi, Y. Liu, J.J. Johnson, M.S. Stack, Urinary-type plasminogen activator receptor (uPAR) modulates oral cancer cell behavior with alteration in p130cas, Mol. Cell. Biochem. 357 (2011) 151–161. doi:10.1007/s11010-011-0885-3.
- [211] W. Yang, W. Han, S. Ye, D. Liu, J. Wu, H. Liu, C. Li, H. Chen, Fibroblast activation protein-α promotes ovarian cancer cell proliferation and invasion via extracellular and intracellular signaling mechanisms, Exp. Mol. Pathol. 95 (2013) 105–110. doi:10.1016/j.yexmp.2013.06.007.
- [212] Y. Wei, J.A. Eble, Z. Wang, J.A. Kreidberg, H.A. Chapman, Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1, Mol. Biol. Cell. 12 (2001) 2975– 2986.
- [213] G.M.S. Ferraris, C. Schulte, V. Buttiglione, V. De Lorenzi, A. Piontini, M. Galluzzi, A. Podesta, C.D. Madsen, N. Sidenius, The interaction between uPAR and vitronectin triggers ligand-independent adhesion signalling by integrins, EMBO J. 33 (2014) 2458–2472. doi:10.15252/embj.201387611.
- [214] C. Schulte, G.M.S. Ferraris, A. Oldani, M. Galluzzi, A. Podestà, L. Puricelli, V. de Lorenzi, C. Lenardi, P. Milani, N. Sidenius, Lamellipodial tension, not integrin/ligand binding, is the crucial factor to realise integrin activation and cell migration, Eur. J. Cell Biol. 95 (2016) 1–14. doi:10.1016/j. ejcb.2015.10.002.
- [215] J. Gu, N. Taniguchi, Regulation of integrin functions by N-glycans, Glycoconj. J. 21 (2004) 9–15. doi:10.1023/B:GLYC.0000043741.47559.30.
- [216] M.E. Janik, M. Przybyło, E. Pocheć, M. Pokrywka, A. Lityńska, Effect of alpha3beta1 and alphavbeta3 integrin glycosylation on interaction of melanoma cells with vitronectin, Acta Biochim. Pol. 57 (2010) 55–61.
- [217] M.E. Kremser, M. Przybyło, D. Hoja-Łukowicz, E. Pocheć, A. Amoresano, A. Carpentieri, M. Bubka, A. Lityńska, Characterisation of alpha3beta1 and alpha(v)beta3 integrin N-oligosaccharides in metastatic melanoma WM9 and WM239 cell lines, Biochim. Biophys. Acta. 1780 (2008) 1421–1431. doi:10.1016/j.bbagen.2008.07.011.
- [218] H. Yamamoto, A. Oviedo, C. Sweeley, T. Saito, J.R. Moskal, Alpha2,6-sialylation of cell-surface N-glycans inhibits glioma formation in vivo, Cancer Res. 61 (2001) 6822–6829.
- [219] A. Lityńska, M. Przybyło, D. Ksiazek, P. Laidler, Differences of alpha3beta1 integrin glycans from different human bladder cell lines, Acta Biochim. Pol. 47 (2000) 427–434.
- [220] E. Pocheć, A. Lityńska, M. Bubka, A. Amoresano, A. Casbarra, Characterization of the oligosaccharide component of alpha3beta1 integrin from human bladder carcinoma cell line T24 and its role in adhesion and migration, Eur. J. Cell Biol. 85 (2006) 47–57. doi:10.1016/j. ejcb.2005.08.010.
- [221] G. Baldwin, V. Novitskaya, R. Sadej, E. Pochec, A. Litynska, C. Hartmann, J. Williams, L. Ashman, J.A. Eble, F. Berditchevski, Tetraspanin CD151 regulates glycosylation of (alpha)3(beta)1 integrin, J. Biol. Chem. 283 (2008) 35445–35454. doi:10.1074/jbc.M806394200.

- [222] C. Saravanan, F.-T. Liu, I.K. Gipson, N. Panjwani, Galectin-3 promotes lamellipodia formation in epithelial cells by interacting with complex N-glycans on alpha3beta1 integrin, J. Cell Sci. 122 (2009) 3684–3693. doi:10.1242/jcs.045674.
- [223] Y. Ren, P. Hao, S.K.A. Law, S.K. Sze, Hypoxia-induced changes to integrin α 3 glycosylation facilitate invasion in epidermoid carcinoma cell line A431, Mol. Cell. Proteomics MCP. 13 (2014) 3126–3137. doi:10.1074/mcp.M114.038505.
- [224] D. Saito, S. Kyakumoto, N. Chosa, M. Ibi, N. Takahashi, N. Okubo, S. Sawada, A. Ishisaki, M. Kamo, Transforming growth factor-β1 induces epithelial-mesenchymal transition and integrin α3β1mediated cell migration of HSC-4 human squamous cell carcinoma cells through Slug, J. Biochem. (Tokyo). 153 (2013) 303–315. doi:10.1093/jb/mvs144.
- [225] Y. Li, K. Yang, Q. Mao, X. Zheng, D. Kong, L. Xie, Inhibition of TGF-beta receptor I by siRNA suppresses the motility and invasiveness of T24 bladder cancer cells via modulation of integrins and matrix metalloproteinase, Int. Urol. Nephrol. 42 (2010) 315–323. doi:10.1007/s11255-009-9620-3.
- [226] J.M. Lamar, K.M. Pumiglia, C.M. DiPersio, An immortalization-dependent switch in integrin function up-regulates MMP-9 to enhance tumor cell invasion, Cancer Res. 68 (2008) 7371–7379. doi:10.1158/0008-5472.CAN-08-1080.
- [227] V. Iyer, K. Pumiglia, C.M. DiPersio, Alpha3beta1 integrin regulates MMP-9 mRNA stability in immortalized keratinocytes: a novel mechanism of integrin-mediated MMP gene expression, J. Cell Sci. 118 (2005) 1185–1195. doi:10.1242/jcs.01708.
- [228] J. Lamar, V. Iyer, C.M. DiPersio, Integrin α3β1 potentiates TGFβ-mediated induction of MMP-9 in immortalized keratinocytes, J. Invest. Dermatol. 128 (2008) 575–586. doi:10.1038/sj.jid.5701042.
- [229] D.S. Missan, K. Mitchell, S. Subbaram, C.M. DiPersio, Integrin α3β1 signaling through MEK/ERK determines alternative polyadenylation of the MMP-9 mRNA transcript in immortalized mouse keratinocytes, PloS One. 10 (2015) e0119539. doi:10.1371/journal.pone.0119539.
- [230] W.M. Longmate, R. Monichan, M.-L. Chu, T. Tsuda, M.G. Mahoney, C.M. DiPersio, Reduced fibulin-2 contributes to loss of basement membrane integrity and skin blistering in mice lacking integrin α3β1 in the epidermis, J. Invest. Dermatol. 134 (2014) 1609–1617. doi:10.1038/jid.2014.10.
- [231] S.J. Kennel, L.J. Foote, R. Falcioni, A. Sonnenberg, C.D. Stringer, C. Crouse, M.E. Hemler, Analysis of the tumor-associated antigen TSP-180. Identity with alpha 6-beta 4 in the integrin superfamily, J. Biol. Chem. 264 (1989) 15515–15521.
- [232] C. Van Waes, K.F. Kozarsky, A.B. Warren, L. Kidd, D. Paugh, M. Liebert, T.E. Carey, The A9 antigen associated with aggressive human squamous carcinoma is structurally and functionally similar to the newly defined integrin alpha 6 beta 4, Cancer Res. 51 (1991) 2395–2402.
- [233] R.L. Stewart, K.L. O'Connor, Clinical significance of the integrin α6β4 in human malignancies, Lab. Investig. J. Tech. Methods Pathol. 95 (2015) 976–986. doi:10.1038/labinvest.2015.82.
- [234] L.K. Diaz, M. Cristofanilli, X. Zhou, K.L. Welch, T.L. Smith, Y. Yang, N. Sneige, A.A. Sahin, M.Z. Gilcrease, Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer, Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc. 18 (2005) 1165–1175. doi:10.1038/modpathol.3800411.
- [235] Y. Masugi, K. Yamazaki, K. Emoto, K. Effendi, H. Tsujikawa, M. Kitago, O. Itano, Y. Kitagawa, M. Sakamoto, Upregulation of integrin β4 promotes epithelial–mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma, Lab. Invest. 95 (2015) 308–319. doi:10.1038/labinvest.2014.166.
- [236] J.D. Aplin, S. Dawson, M.W. Seif, Abnormal expression of integrin alpha 6 beta 4 in cervical intraepithelial neoplasia, Br. J. Cancer. 74 (1996) 240–245.
- [237] T. Tennenbaum, A.K. Weiner, A.J. Belanger, A.B. Glick, H. Hennings, S.H. Yuspa, The suprabasal expression of alpha 6 beta 4 integrin is associated with a high risk for malignant progression in mouse skin carcinogenesis, Cancer Res. 53 (1993) 4803–4810.

- [238] C.V. Waes, D.M. Surh, Z. Chen, M. Kirby, J.S. Rhim, R. Brager, R.B. Sessions, J. Poore, G.T. Wolf, T.E. Carey, Increase in Suprabasilar Integrin Adhesion Molecule Expression in Human Epidermal Neoplasms Accompanies Increased Proliferation Occurring with Immortalization and Tumor Progression, Cancer Res. 55 (1995) 5434–5444.
- [239] E. Carico, D. French, B. Bucci, R. Falcioni, A. Vecchione, R. Mariani-Costantini, Integrin beta 4 expression in the neoplastic progression of cervical epithelium, Gynecol. Oncol. 49 (1993) 61–66. doi:10.1006/gyno.1993.1087.
- [240] H.B. Grossman, R.W. Washington, T.E. Carey, M. Liebert, Alterations in antigen expression in superficial bladder cancer, J. Cell. Biochem. 50 (1992) 63–68. doi:10.1002/jcb.240501313.
- [241] A.E. Cress, I. Rabinovitz, W. Zhu, R.B. Nagle, The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression, Cancer Metastasis Rev. 14 (1995) 219–228.
- [242] T.L. Davis, A.E. Cress, B.L. Dalkin, R.B. Nagle, Unique expression pattern of the alpha6beta4 integrin and laminin-5 in human prostate carcinoma, The Prostate. 46 (2001) 240–248.
- [243] R.B. Nagle, J. Hao, J.D. Knox, B.L. Dalkin, V. Clark, A.E. Cress, Expression of hemidesmosomal and extracellular matrix proteins by normal and malignant human prostate tissue, Am. J. Pathol. 146 (1995) 1498–1507.
- [244] M.V. Allen, G.J. Smith, R. Juliano, S.J. Maygarden, J.L. Mohler, Downregulation of the beta4 integrin subunit in prostatic carcinoma and prostatic intraepithelial neoplasia, Hum. Pathol. 29 (1998) 311–318.
- [245] K. Rossen, K.K. Dahlstrøm, A.M. Mercurio, U.M. Wewer, Expression of the alpha 6 beta 4 integrin by squamous cell carcinomas and basal cell carcinomas: possible relation to invasive potential?, Acta Derm. Venereol. 74 (1994) 101–105.
- [246] D.M. Owens, M.R. Romero, C. Gardner, F.M. Watt, Suprabasal alpha6beta4 integrin expression in epidermis results in enhanced tumourigenesis and disruption of TGFbeta signalling, J. Cell Sci. 116 (2003) 3783–3791. doi:10.1242/jcs.00725.
- [247] C.S. Yoon, K.D. Kim, S.N. Park, S.W. Cheong, alpha(6) Integrin is the main receptor of human papillomavirus type 16 VLP, Biochem. Biophys. Res. Commun. 283 (2001) 668–673. doi:10.1006/ bbrc.2001.4838.
- [248] H.-S. Huang, P.F. Lambert, Use of an in vivo animal model for assessing the role of integrin $\alpha(6)$ $\beta(4)$ and syndecan-1 in early steps in papillomavirus infection, Virology. 433 (2012) 395–400. doi:10.1016/j.virol.2012.08.032.
- [249] P. Aksoy, C.Y. Abban, E. Kiyashka, W. Qiang, P.I. Meneses, HPV16 infection of HaCaTs is dependent on β4 integrin, and α6 integrin processing, Virology. 449 (2014) 45–52. doi:10.1016/j. virol.2013.10.034.
- [250] M. Oldak, R.B. Maksym, T. Sperling, M. Yaniv, H. Smola, H.J. Pfister, J. Malejczyk, S. Smola, Human papillomavirus type 8 E2 protein unravels JunB/Fra-1 as an activator of the beta4-integrin gene in human keratinocytes, J. Virol. 84 (2010) 1376–1386. doi:10.1128/JVI.01220-09.
- [251] M. Oldak, H. Smola, M. Aumailley, F. Rivero, H. Pfister, S. Smola-Hess, The human papillomavirus type 8 E2 protein suppresses beta4-integrin expression in primary human keratinocytes, J. Virol. 78 (2004) 10738–10746. doi:10.1128/JVI.78.19.10738-10746.2004.
- [252] W. Guo, Y. Pylayeva, A. Pepe, T. Yoshioka, W.J. Muller, G. Inghirami, F.G. Giancotti, Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis, Cell. 126 (2006) 489–502. doi:10.1016/j.cell.2006.05.047.
- [253] R. Falcioni, A. Antonini, P. Nisticò, S. Di Stefano, M. Crescenzi, P.G. Natali, A. Sacchi, Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines, Exp. Cell Res. 236 (1997) 76–85.
- [254] M.M. Santoro, G. Gaudino, P.C. Marchisio, The MSP Receptor Regulates $\alpha6\beta4$ and $\alpha3\beta1$ Integrins via 14-3-3 Proteins in Keratinocyte Migration, Dev. Cell. 5 (2003) 257–271. doi:10.1016/S1534-5807(03)00201-6.

- [255] A. Bertotti, P.M. Comoglio, L. Trusolino, β4 Integrin Is a Transforming Molecule that Unleashes Met Tyrosine Kinase Tumorigenesis, Cancer Res. 65 (2005) 10674–10679. doi:10.1158/0008-5472. CAN-05-2827.
- [256] M. Fujita, K. Ieguchi, P. Davari, S. Yamaji, Y. Taniguchi, K. Sekiguchi, Y.K. Takada, Y. Takada, Crosstalk between integrin α6β4 and insulin-like growth factor-1 receptor (IGF1R) through direct α6β4 binding to IGF1 and subsequent α6β4-IGF1-IGF1R ternary complex formation in anchorage-independent conditions, J. Biol. Chem. 287 (2012) 12491–12500. doi:10.1074/jbc.M111.304170.
- [257] F.G. Giancotti, Targeting integrin beta4 for cancer and anti-angiogenic therapy, Trends Pharmacol. Sci. 28 (2007) 506–511. doi:10.1016/j.tips.2007.08.004.
- [258] A. Mariotti, P.A. Kedeshian, M. Dans, A.M. Curatola, L. Gagnoux-Palacios, F.G. Giancotti, EGF-R signaling through Fyn kinase disrupts the function of integrin alpha6beta4 at hemidesmosomes: role in epithelial cell migration and carcinoma invasion, J. Cell Biol. 155 (2001) 447–458. doi:10.1083/icb.200105017.
- [259] Y.-L. Tai, P.-Y. Chu, I.-R. Lai, M.-Y. Wang, H.-Y. Tseng, J.-L. Guan, J.-Y. Liou, T.-L. Shen, An EGFR/Src-dependent β4 integrin/FAK complex contributes to malignancy of breast cancer, Sci. Rep. 5 (2015) 16408. doi:10.1038/srep16408.
- [260] L. Trusolino, A. Bertotti, P.M. Comoglio, A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth, Cell. 107 (2001) 643–654.
- [261] M.Z. Gilcrease, X. Zhou, X. Lu, W.A. Woodward, B.E. Hall, P.J. Morrissey, Alpha6beta4 integrin crosslinking induces EGFR clustering and promotes EGF-mediated Rho activation in breast cancer, J. Exp. Clin. Cancer Res. CR. 28 (2009) 67. doi:10.1186/1756-9966-28-67.
- [262] H. Wang, L. Leavitt, R. Ramaswamy, A.C. Rapraeger, Interaction of syndecan and alpha6beta4 integrin cytoplasmic domains: regulation of ErbB2-mediated integrin activation, J. Biol. Chem. 285 (2010) 13569–13579. doi:10.1074/jbc.M110.102137.
- [263] H. Wang, H. Jin, D.M. Beauvais, A.C. Rapraeger, Cytoplasmic domain interactions of syndecan-1 and syndecan-4 with $\alpha 6\beta 4$ integrin mediate human epidermal growth factor receptor (HER1 and HER2)-dependent motility and survival, J. Biol. Chem. 289 (2014) 30318–30332. doi:10.1074/jbc. M114.586438.
- [264] F. Mainiero, C. Murgia, K.K. Wary, A.M. Curatola, A. Pepe, M. Blumemberg, J.K. Westwick, C.J. Der, F.G. Giancotti, The coupling of alpha6beta4 integrin to Ras-MAP kinase pathways mediated by Shc controls keratinocyte proliferation, EMBO J. 16 (1997) 2365–2375. doi:10.1093/emboj/16.9.2365.
- [265] L. Gagnoux-Palacios, M. Dans, W. van't Hof, A. Mariotti, A. Pepe, G. Meneguzzi, M.D. Resh, F.G. Giancotti, Compartmentalization of integrin alpha6beta4 signaling in lipid rafts, J. Cell Biol. 162 (2003) 1189–1196. doi:10.1083/jcb.200305006.
- [266] J. Chung, R.E. Bachelder, E.A. Lipscomb, L.M. Shaw, A.M. Mercurio, Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells, J. Cell Biol. 158 (2002) 165–174. doi:10.1083/jcb.200112015.
- [267] A.M. Mercurio, R.E. Bachelder, R.C. Bates, J. Chung, Autocrine signaling in carcinoma: VEGF and the α6β4 integrin, Semin. Cancer Biol. 14 (2004) 115–122. doi:10.1016/j.semcancer.2003.09.016.
- [268] L.M. Shaw, I. Rabinovitz, H.H. Wang, A. Toker, A.M. Mercurio, Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion, Cell. 91 (1997) 949–960.
- [269] V. Gabarra, S. Cho, M. Ramirez, Y. Ren, L.L. Chen, A. Cheung, X. Cao, R. Rennard, K.R. Unruh, C.P. Graff, B. Browning, H.A. Huet, K. McLachlan, Antibodies directed to alpha6beta4 highlight the adhesive and signaling functions of the integrin in breast cancer cell lines, Cancer Biol. Ther. 9 (2010) 437–445.
- [270] G. Bon, V. Folgiero, G. Bossi, L. Felicioni, A. Marchetti, A. Sacchi, R. Falcioni, Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 12 (2006) 3280–3287. doi:10.1158/1078-0432.CCR-05-2223.

- [271] C. Fan, H. Su, J. Zhao, B. Zhao, S. Zhang, J. Miao, A novel copper complex of salicylaldehyde pyrazole hydrazone induces apoptosis through up-regulating integrin beta4 in H322 lung carcinoma cells, Eur. J. Med. Chem. 45 (2010) 1438–1446. doi:10.1016/j.ejmech.2009.12.048.
- [272] C. Fan, J. Zhao, B. Zhao, S. Zhang, J. Miao, Novel complex of copper and a salicylaldehyde pyrazole hydrazone derivative induces apoptosis through up-regulating integrin beta 4 in vascular endothelial cells, Chem. Res. Toxicol. 22 (2009) 1517–1525. doi:10.1021/tx900111y.
- [273] X. Liu, J. Zhao, J. Xu, B. Zhao, Y. Zhang, S. Zhang, J. Miao, Protective effects of a benzoxazine derivative against oxidized LDL-induced apoptosis and the increases of integrin beta4, ROS, NFkappaB and P53 in human umbilical vein endothelial cells, Bioorg. Med. Chem. Lett. 19 (2009) 2896–2900. doi:10.1016/j.bmcl.2009.03.070.
- [274] L. Su, B. Zhao, X. Lv, N. Wang, J. Zhao, S. Zhang, J. Miao, Safrole oxide induces neuronal apoptosis through inhibition of integrin beta4/SOD activity and elevation of ROS/NADPH oxidase activity, Life Sci. 80 (2007) 999–1006. doi:10.1016/j.lfs.2006.11.041.
- [275] K.-W. Zhao, Q.-T. Zhao, S.-L. Zhang, J.-Y. Miao, Integrin beta4 mAb inhibited apoptosis induced by deprivation of growth factors in vascular endothelial cells, Acta Pharmacol. Sin. 25 (2004) 733–737.
- [276] Y. Ishii, A. Ochiai, T. Yamada, S. Akimoto, K. Yanagihara, M. Kitajima, S. Hirohashi, Integrin alpha6beta4 as a suppressor and a predictive marker for peritoneal dissemination in human gastric cancer, Gastroenterology. 118 (2000) 497–506.
- [277] R.E. Bachelder, A. Marchetti, R. Falcioni, S. Soddu, A.M. Mercurio, Activation of p53 function in carcinoma cells by the alpha6beta4 integrin, J. Biol. Chem. 274 (1999) 20733–20737.
- [278] G. Bon, S.E. Di Carlo, V. Folgiero, P. Avetrani, C. Lazzari, G. D'Orazi, M.F. Brizzi, A. Sacchi, S. Soddu, G. Blandino, M. Mottolese, R. Falcioni, Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression, Cancer Res. 69 (2009) 5978–5986. doi:10.1158/0008-5472.CAN-09-0244.
- [279] R.E. Bachelder, M.J. Ribick, A. Marchetti, R. Falcioni, S. Soddu, K.R. Davis, A.M. Mercurio, p53 inhibits alpha 6 beta 4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB, J. Cell Biol. 147 (1999) 1063–1072.
- [280] J.-G. Lee, J.-H. Ahn, T. Jin Kim, J. Ho Lee, J.-H. Choi, Mutant p53 promotes ovarian cancer cell adhesion to mesothelial cells via integrin β4 and Akt signals, Sci. Rep. 5 (2015) 12642. doi:10.1038/srep12642.
- [281] M. Dajee, M. Lazarov, J.Y. Zhang, T. Cai, C.L. Green, A.J. Russell, M.P. Marinkovich, S. Tao, Q. Lin, Y. Kubo, P.A. Khavari, NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia, Nature. 421 (2003) 639–643. doi:10.1038/nature01283.
- [282] E.A. Lipscomb, K.J. Simpson, S.R. Lyle, J.E. Ring, A.S. Dugan, A.M. Mercurio, The alpha6beta4 integrin maintains the survival of human breast carcinoma cells in vivo, Cancer Res. 65 (2005) 10970–10976. doi:10.1158/0008-5472.CAN-05-2327.
- [283] J.C. Friedland, J.N. Lakins, M.G. Kazanietz, J. Chernoff, D. Boettiger, V.M. Weaver, alpha6beta4 integrin activates Rac-dependent p21-activated kinase 1 to drive NF-kappaB-dependent resistance to apoptosis in 3D mammary acini, J. Cell Sci. 120 (2007) 3700–3712. doi:10.1242/jcs.03484.
- [284] N. Zahir, J.N. Lakins, A. Russell, W. Ming, C. Chatterjee, G.I. Rozenberg, M.P. Marinkovich, V.M. Weaver, Autocrine laminin-5 ligates alpha6beta4 integrin and activates RAC and NFkappaB to mediate anchorage-independent survival of mammary tumors, J. Cell Biol. 163 (2003) 1397–1407. doi:10.1083/jcb.200302023.
- [285] R. Derynck, R.J. Akhurst, A. Balmain, TGF-beta signaling in tumor suppression and cancer progression, Nat. Genet. 29 (2001) 117–129. doi:10.1038/ng1001-117.
- [286] L.M. Wakefield, A.B. Roberts, TGF-beta signaling: positive and negative effects on tumorigenesis, Curr. Opin. Genet. Dev. 12 (2002) 22–29.

- [287] T.S. Hiran, J.E. Mazurkiewicz, P. Kreienberg, F.L. Rice, S.E. LaFlamme, Endothelial expression of the $\alpha6\beta4$ integrin is negatively regulated during angiogenesis, J. Cell Sci. 116 (2003) 3771–3781. doi:10.1242/jcs.00681.
- [288] D. Desai, P. Singh, L. Van De Water, S.E. Laflamme, Dynamic Regulation of Integrin α6β4 During Angiogenesis: Potential Implications for Pathogenic Wound Healing, Adv. Wound Care. 2 (2013) 401–409. doi:10.1089/wound.2013.0455.
- [289] T.-H. Lee, S. Seng, H. Li, S.J. Kennel, H.K. Avraham, S. Avraham, Integrin Regulation by Vascular Endothelial Growth Factor in Human Brain Microvascular Endothelial Cells ROLE OF α6β1 INTEGRIN IN ANGIOGENESIS, J. Biol. Chem. 281 (2006) 40450–40460. doi:10.1074/jbc. M607525200.
- [290] S.N. Nikolopoulos, P. Blaikie, T. Yoshioka, W. Guo, F.G. Giancotti, Integrin beta4 signaling promotes tumor angiogenesis, Cancer Cell. 6 (2004) 471–483. doi:10.1016/j.ccr.2004.09.029.
- [291] C. Feng, C. Ye, X. Liu, H. Ma, M. Li, Beta4 integrin is involved in statin-induced endothelial cell death, Biochem. Biophys. Res. Commun. 323 (2004) 858–864. doi:10.1016/j.bbrc.2004.08.171.
- [292] L. Wang, Z. Dong, Y. Zhang, J. Miao, The roles of integrin β4 in vascular endothelial cells, J. Cell. Physiol. 227 (2012) 474–478. doi:10.1002/jcp.22769.
- [293] A.M. Mercurio, E.A. Lipscomb, R.E. Bachelder, Non-angiogenic functions of VEGF in breast cancer, J. Mammary Gland Biol. Neoplasia. 10 (2005) 283–290. doi:10.1007/s10911-006-9001-9.
- [294] A.M. Mercurio, I. Rabinovitz, Towards a mechanistic understanding of tumor invasion-lessons from the alpha6beta 4 integrin, Semin. Cancer Biol. 11 (2001) 129–141. doi:10.1006/scbi.2000.0364.
- [295] G. Giannelli, S. Astigiano, S. Antonaci, M. Morini, O. Barbieri, D.M. Noonan, A. Albini, Role of the alpha3beta1 and alpha6beta4 integrins in tumor invasion, Clin. Exp. Metastasis. 19 (2002) 217–223.
- [296] C.A.W. Geuijen, A. Sonnenberg, Dynamics of the alpha6beta4 integrin in keratinocytes, Mol. Biol. Cell. 13 (2002) 3845–3858. doi:10.1091/mbc.02-01-0601.
- [297] K. Raymond, M. Kreft, H. Janssen, J. Calafat, A. Sonnenberg, Keratinocytes display normal proliferation, survival and differentiation in conditional beta4-integrin knockout mice, J. Cell Sci. 118 (2005) 1045–1060. doi:10.1242/jcs.01689.
- [298] J. Uematsu, Y. Nishizawa, A. Sonnenberg, K. Owaribe, Demonstration of type II hemidesmosomes in a mammary gland epithelial cell line, BMGE-H, J. Biochem. (Tokyo). 115 (1994) 469–476.
- [299] J.F. Beaulieu, Extracellular matrix components and integrins in relationship to human intestinal epithelial cell differentiation, Prog. Histochem. Cytochem. 31 (1997) 1–78.
- [300] A.M. Mercurio, I. Rabinovitz, L.M. Shaw, The alpha 6 beta 4 integrin and epithelial cell migration, Curr. Opin. Cell Biol. 13 (2001) 541–545.
- [301] J. Tang, G. Wang, M. Zhang, F. Li, Y. Sang, B. Wang, K. Hu, Y. Wu, R. Luo, D. Liao, J. Cao, X. Wang, L. Wang, R. Zhang, X. Zhang, W. Deng, D. Xie, R. Xu, T. Kang, Paradoxical role of CBX8 in proliferation and metastasis of colorectal cancer, Oncotarget. 5 (2014) 10778–10790. doi:10.18632/oncotarget.2502.
- [302] C.D. Lawson, K. Burridge, The on-off relationship of Rho and Rac during integrin-mediated adhesion and cell migration, Small GTPases. 5 (2014) e27958. doi:10.4161/sgtp.27958.
- [303] B.P. Nguyen, S.G. Gil, W.G. Carter, Deposition of laminin 5 by keratinocytes regulates integrin adhesion and signaling, J. Biol. Chem. 275 (2000) 31896–31907. doi:10.1074/jbc.M006379200.
- [304] C.E. Pullar, B.S. Baier, Y. Kariya, A.J. Russell, B.A.J. Horst, M.P. Marinkovich, R.R. Isseroff, beta4 integrin and epidermal growth factor coordinately regulate electric field-mediated directional migration via Rac1, Mol. Biol. Cell. 17 (2006) 4925–4935. doi:10.1091/mbc.E06-05-0433.
- [305] Z. Cruz-Monserrate, K.L. O'Connor, Integrin alpha 6 beta 4 promotes migration, invasion through Tiam1 upregulation, and subsequent Rac activation, Neoplasia N. Y. N. 10 (2008) 408–417.

- [306] R.V. Mula, V. Bhatia, M. Falzon, PTHrP promotes colon cancer cell migration and invasion in an integrin α 6 β 4-dependent manner through activation of Rac1, Cancer Lett. 298 (2010) 119–127. doi:10.1016/j.canlet.2010.06.009.
- [307] K.L. O'Connor, M. Chen, L.N. Towers, Integrin α6β4 cooperates with LPA signaling to stimulate Rac through AKAP-Lbc-mediated RhoA activation, Am. J. Physiol. Cell Physiol. 302 (2012) C605-614. doi:10.1152/ajpcell.00095.2011.
- [308] A.J. Russell, E.F. Fincher, L. Millman, R. Smith, V. Vela, E.A. Waterman, C.N. Dey, S. Guide, V.M. Weaver, M.P. Marinkovich, Alpha 6 beta 4 integrin regulates keratinocyte chemotaxis through differential GTPase activation and antagonism of alpha 3 beta 1 integrin, J. Cell Sci. 116 (2003) 3543–3556. doi:10.1242/jcs.00663.
- [309] S.N. Nikolopoulos, P. Blaikie, T. Yoshioka, W. Guo, C. Puri, C. Tacchetti, F.G. Giancotti, Targeted deletion of the integrin beta4 signaling domain suppresses laminin-5-dependent nuclear entry of mitogen-activated protein kinases and NF-kappaB, causing defects in epidermal growth and migration, Mol. Cell. Biol. 25 (2005) 6090–6102. doi:10.1128/MCB.25.14.6090-6102.2005.
- [310] K.L. O'Connor, B.K. Nguyen, A.M. Mercurio, RhoA function in lamellae formation and migration is regulated by the alpha6beta4 integrin and cAMP metabolism, J. Cell Biol. 148 (2000) 253–258.
- [311] S. Jauliac, C. López-Rodriguez, L.M. Shaw, L.F. Brown, A. Rao, A. Toker, The role of NFAT transcription factors in integrin-mediated carcinoma invasion, Nat. Cell Biol. 4 (2002) 540–544. doi:10.1038/ ncb816.
- [312] T.H. Kim, H.I. Kim, Y.H. Soung, L.A. Shaw, J. Chung, Integrin (alpha6beta4) signals through Src to increase expression of S100A4, a metastasis-promoting factor: implications for cancer cell invasion, Mol. Cancer Res. MCR. 7 (2009) 1605–1612. doi:10.1158/1541-7786.MCR-09-0102.
- [313] M. Chen, K.L. O'Connor, Integrin alpha6beta4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells, Oncogene. 24 (2005) 5125–5130. doi:10.1038/sj.onc.1208729.
- [314] Y. Kishi, S. Okudaira, M. Tanaka, K. Hama, D. Shida, J. Kitayama, T. Yamori, J. Aoki, T. Fujimaki, H. Arai, Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid, J. Biol. Chem. 281 (2006) 17492–17500. doi:10.1074/jbc.M601803200.
- [315] M. Chen, M. Sinha, B.A. Luxon, A.R. Bresnick, K.L. O'Connor, Integrin alpha6beta4 controls the expression of genes associated with cell motility, invasion, and metastasis, including S100A4/ metastasin, J. Biol. Chem. 284 (2009) 1484–1494. doi:10.1074/jbc.M803997200.
- [316] S. Tarabykina, T.R.L. Griffiths, E. Tulchinsky, J.K. Mellon, I.B. Bronstein, M. Kriajevska, Metastasis-associated protein S100A4: spotlight on its role in cell migration, Curr. Cancer Drug Targets. 7 (2007) 217–228.
- [317] R. Barraclough, Calcium-binding protein S100A4 in health and disease, Biochim. Biophys. Acta. 1448 (1998) 190–199.
- [318] A. Miyazaki, T. Ohkubo, M. Hatta, H. Ishikawa, J. Yamazaki, Integrin α6β4 and TRPV1 channel coordinately regulate directional keratinocyte migration, Biochem. Biophys. Res. Commun. 458 (2015) 161–167. doi:10.1016/j.bbrc.2015.01.086.
- [319] Q. Chen, R. Xu, C. Zeng, Q. Lu, D. Huang, C. Shi, W. Zhang, L. Deng, R. Yan, H. Rao, G. Gao, S. Luo, Down-regulation of Gli transcription factor leads to the inhibition of migration and invasion of ovarian cancer cells via integrin β4-mediated FAK signaling, PloS One. 9 (2014) e88386. doi:10.1371/journal.pone.0088386.
- [320] M. Abdel-Ghany, H.-C. Cheng, R.C. Elble, B.U. Pauli, Focal adhesion kinase activated by beta(4) integrin ligation to mCLCA1 mediates early metastatic growth, J. Biol. Chem. 277 (2002) 34391–34400. doi:10.1074/jbc.M205307200.

- [321] I. Lakshmanan, S. Rachagani, R. Hauke, S.R. Krishn, S. Paknikar, P. Seshacharyulu, S. Karmakar, R.K. Nimmakayala, G. Kaushik, S.L. Johansson, G.B. Carey, M.P. Ponnusamy, S. Kaur, S.K. Batra, A.K. Ganti, MUC5AC interactions with integrin β4 enhances the migration of lung cancer cells through FAK signaling, Oncogene. (2016). doi:10.1038/onc.2015.478.
- [322] B.U. Sehgal, P.J. DeBiase, S. Matzno, T.-L. Chew, J.N. Claiborne, S.B. Hopkinson, A. Russell, M.P. Marinkovich, J.C.R. Jones, Integrin beta4 regulates migratory behavior of keratinocytes by determining laminin-332 organization, J. Biol. Chem. 281 (2006) 35487–35498. doi:10.1074/jbc. M606317200.
- [323] I. Rabinovitz, I.K. Gipson, A.M. Mercurio, Traction forces mediated by alpha6beta4 integrin: implications for basement membrane organization and tumor invasion, Mol. Biol. Cell. 12 (2001) 4030–4043.
- [324] O. Schofield, D. Kist, A. Lucas, E. Wayner, W. Carter, C. Zachary, Abnormal expression of epiligrin and alpha 6 beta 4 integrin in basal cell carcinoma, Dermatol. Surg. Off. Publ. Am. Soc. Dermatol. Surg. Al. 24 (1998) 555–559.
- [325] B.L. Carpenter, M. Chen, T. Knifley, K.A. Davis, S.M.W. Harrison, R.L. Stewart, K.L. O'Connor, Integrin α6β4 Promotes Autocrine Epidermal Growth Factor Receptor (EGFR) Signaling to Stimulate Migration and Invasion toward Hepatocyte Growth Factor (HGF), J. Biol. Chem. 290 (2015) 27228–27238. doi:10.1074/jbc.M115.686873.
- [326] N. Daemi, N. Thomasset, J.C. Lissitzky, J. Dumortier, M.F. Jacquier, C. Pourreyron, P. Rousselle, J.A. Chayvialle, L. Remy, Anti-beta4 integrin antibodies enhance migratory and invasive abilities of human colon adenocarcinoma cells and their MMP-2 expression, Int. J. Cancer J. Int. Cancer. 85 (2000) 850–856.
- [327] R. Sadej, A. Grudowska, L. Turczyk, R. Kordek, H.M. Romanska, CD151 in cancer progression and metastasis: a complex scenario, Lab. Investig. J. Tech. Methods Pathol. 94 (2014) 41–51. doi:10.1038/labinvest.2013.136.
- [328] M. Zöller, Tetraspanins: push and pull in suppressing and promoting metastasis, Nat. Rev. Cancer. 9 (2009) 40–55. doi:10.1038/nrc2543.
- [329] M. Hasegawa, M. Furuya, Y. Kasuya, M. Nishiyama, T. Sugiura, T. Nikaido, Y. Momota, M. Ichinose, S. Kimura, CD151 dynamics in carcinoma-stroma interaction: integrin expression, adhesion strength and proteolytic activity, Lab. Investig. J. Tech. Methods Pathol. 87 (2007) 882–892. doi:10.1038/labinvest.3700657.
- [330] D.E. White, W.J. Muller, Multifaceted roles of integrins in breast cancer metastasis, J. Mammary Gland Biol. Neoplasia. 12 (2007) 135–142. doi:10.1007/s10911-007-9045-5.
- [331] R.L. Stewart, K.L. O'Connor, Clinical significance of the integrin α6β4 in human malignancies, Lab. Investig. J. Tech. Methods Pathol. 95 (2015) 976–986. doi:10.1038/labinvest.2015.82.
- [332] R. Shi, J. Li, F. Tang, Y.I. Luo, C.-Q. Tu, Identification and functional study of osteosarcoma metastasis marker genes, Oncol. Lett. 10 (2015) 1848–1852. doi:10.3892/ol.2015.3444.
- [333] M.Z. Gilcrease, S.K. Kilpatrick, W.A. Woodward, X. Zhou, M.M. Nicolas, L.J. Corley, G.N. Fuller, S.L. Tucker, L.K. Diaz, T.A. Buchholz, J.A. Frost, Coexpression of alpha6beta4 integrin and guanine nucleotide exchange factor Net1 identifies node-positive breast cancer patients at high risk for distant metastasis, Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol. 18 (2009) 80–86. doi:10.1158/1055-9965.EPI-08-0842.
- [334] T.-H. Lee, H.K. Avraham, S. Jiang, S. Avraham, Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability, J. Biol. Chem. 278 (2003) 5277–5284. doi:10.1074/ jbc.M210063200.
- [335] S. Shen, J. Fan, B. Cai, Y. Lv, M. Zeng, Y. Hao, F.G. Giancotti, B.M. Fu, Vascular endothelial growth factor enhances cancer cell adhesion to microvascular endothelium in vivo, Exp. Physiol. 95 (2010) 369–379. doi:10.1113/expphysiol.2009.050260.

- [336] B.M. Fu, S. Shen, Acute VEGF effect on solute permeability of mammalian microvessels in vivo, Microvasc. Res. 68 (2004) 51–62. doi:10.1016/j.mvr.2004.03.004.
- [337] J. Fan, B. Cai, M. Zeng, Y. Hao, F.G. Giancotti, B.M. Fu, Integrin β4 signaling promotes mammary tumor cell adhesion to brain microvascular endothelium by inducing ErbB2-mediated secretion of VEGF, Ann. Biomed. Eng. 39 (2011) 2223–2241. doi:10.1007/s10439-011-0321-6.
- [338] A. Hoshino, B. Costa-Silva, T.-L. Shen, G. Rodrigues, A. Hashimoto, M. Tesic Mark, H. Molina, S. Kohsaka, A. Di Giannatale, S. Ceder, S. Singh, C. Williams, N. Soplop, K. Uryu, L. Pharmer, T. King, L. Bojmar, A.E. Davies, Y. Ararso, T. Zhang, H. Zhang, J. Hernandez, J.M. Weiss, V.D. Dumont-Cole, K. Kramer, L.H. Wexler, A. Narendran, G.K. Schwartz, J.H. Healey, P. Sandstrom, K. Jørgen Labori, E.H. Kure, P.M. Grandgenett, M.A. Hollingsworth, M. de Sousa, S. Kaur, M. Jain, K. Mallya, S.K. Batra, W.R. Jarnagin, M.S. Brady, O. Fodstad, V. Muller, K. Pantel, A.J. Minn, M.J. Bissell, B.A. Garcia, Y. Kang, V.K. Rajasekhar, C.M. Ghajar, I. Matei, H. Peinado, J. Bromberg, D. Lyden, Tumour exosome integrins determine organotropic metastasis, Nature. 527 (2015) 329–335. doi:10.1038/nature15756.
- [339] P.T. Yu, M. Babicky, D. Jaquish, R. French, K. Marayuma, E. Mose, S. Niessen, H. Hoover, D. Shields, D. Cheresh, B.F. Cravatt, A.M. Lowy, The RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome, Int. J. Cancer J. Int. Cancer. 131 (2012) 1744–1754. doi:10.1002/ijc.27447.
- [340] D. Gambaletta, A. Marchetti, L. Benedetti, A.M. Mercurio, A. Sacchi, R. Falcioni, Cooperative signaling between alpha(6)beta(4) integrin and ErbB-2 receptor is required to promote phosphatidylinositol 3-kinase-dependent invasion, J. Biol. Chem. 275 (2000) 10604–10610.
- [341] V. Folgiero, P. Avetrani, G. Bon, S.E. Di Carlo, A. Fabi, C. Nisticò, P. Vici, E. Melucci, S. Buglioni, L. Perracchio, I. Sperduti, L. Rosanò, A. Sacchi, M. Mottolese, R. Falcioni, Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas, PloS One. 3 (2008) e1592. doi:10.1371/journal.pone.0001592.
- [342] Y.H. Soung, J.L. Clifford, J. Chung, Crosstalk between integrin and receptor tyrosine kinase signaling in breast carcinoma progression, BMB Rep. 43 (2010) 311–318.
- [343] C.H. Streuli, N. Akhtar, Signal co-operation between integrins and other receptor systems, Biochem. J. 418 (2009) 491–506. doi:10.1042/BJ20081948.
- [344] C. Schreider, G. Peignon, S. Thenet, J. Chambaz, M. Pinçon-Raymond, Integrin-mediated functional polarization of Caco-2 cells through E-cadherin--actin complexes, J. Cell Sci. 115 (2002) 543–552.
- [345] E. Hintermann, N. Yang, D. O'Sullivan, J.M.G. Higgins, V. Quaranta, Integrin alpha6beta4-erbB2 complex inhibits haptotaxis by up-regulating E-cadherin cell-cell junctions in keratinocytes, J. Biol. Chem. 280 (2005) 8004–8015. doi:10.1074/jbc.M406301200.
- [346] X. Yang, B. Pursell, S. Lu, T.-K. Chang, A.M. Mercurio, Regulation of beta 4-integrin expression by epigenetic modifications in the mammary gland and during the epithelial-to-mesenchymal transition, J. Cell Sci. 122 (2009) 2473–2480. doi:10.1242/jcs.049148.
- [347] M. Takkunen, R. Grenman, M. Hukkanen, M. Korhonen, A. García de Herreros, I. Virtanen, Snail-dependent and -independent epithelial-mesenchymal transition in oral squamous carcinoma cells, J. Histochem. Cytochem. Off. J. Histochem. Soc. 54 (2006) 1263–1275. doi:10.1369/jhc.6A6958.2006.
- [348] M. Emadi Baygi, Z.-S. Soheili, F. Essmann, A. Deezagi, R. Engers, W. Goering, W.A. Schulz, Slug/ SNAI2 regulates cell proliferation and invasiveness of metastatic prostate cancer cell lines, Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med. 31 (2010) 297–307. doi:10.1007/s13277-010-0037-5.
- [349] J. Du, S. Hong, L. Dong, B. Cheng, L. Lin, B. Zhao, Y.-G. Chen, X. Chen, Dynamic Sialylation in Transforming Growth Factor-β (TGF-β)-induced Epithelial to Mesenchymal Transition, J. Biol. Chem. 290 (2015) 12000–12013. doi:10.1074/jbc.M115.636969.

- [350] T. Uemura, K. Shiozaki, K. Yamaguchi, S. Miyazaki, S. Satomi, K. Kato, H. Sakuraba, T. Miyagi, Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta4, Oncogene. 28 (2009) 1218–1229. doi:10.1038/onc.2008.471.
- [351] J.-Y. Ho, F.-W. Chang, F.S. Huang, J.-M. Liu, Y.-P. Liu, S.-P. Chen, Y.-L. Liu, K.-C. Cheng, C.-P. Yu, R.-J. Hsu, Estrogen Enhances the Cell Viability and Motility of Breast Cancer Cells through the ERα-ΔNp63-Integrin β4 Signaling Pathway, PloS One. 11 (2016) e0148301. doi:10.1371/journal. pone.0148301.
- [352] V. Bhatia, R.V. Mula, N.L. Weigel, M. Falzon, Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase/ Akt signaling, Mol. Cancer Res. MCR. 7 (2009) 1119–1131. doi:10.1158/1541-7786.MCR-08-0568.
- [353] L. Bonaccorsi, V. Carloni, M. Muratori, A. Salvadori, A. Giannini, M. Carini, M. Serio, G. Forti, E. Baldi, Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype, Endocrinology. 141 (2000) 3172–3182. doi:10.1210/ endo.141.9.7640.
- [354] O. Nagakawa, T. Akashi, Y. Hayakawa, A. Junicho, K. Koizumi, Y. Fujiuchi, Y. Furuya, T. Matsuda, H. Fuse, I. Saiki, Differential expression of integrin subunits in DU-145/AR prostate cancer cells, Oncol. Rep. 12 (2004) 837–841.
- [355] J.G. Baust, D.P. Klossner, R.G. Vanbuskirk, A.A. Gage, V. Mouraviev, T.J. Polascik, J.M. Baust, Integrin involvement in freeze resistance of androgen-insensitive prostate cancer, Prostate Cancer Prostatic Dis. 13 (2010) 151–161. doi:10.1038/pcan.2009.59.
- [356] K. Raymond, M. Kreft, J.-Y. Song, H. Janssen, A. Sonnenberg, Dual Role of alpha6beta4 integrin in epidermal tumor growth: tumor-suppressive versus tumor-promoting function, Mol. Biol. Cell. 18 (2007) 4210–4221. doi:10.1091/mbc.E06-08-0720.
- [357] T. Mohri, Y. Adachi, S. Ikehara, K. Hioki, R. Tokunaga, S. Taketani, Activated Rac1 selectively upregulates the expression of integrin alpha6beta4 and induces cell adhesion and membrane ruffles of nonadherent colon cancer Colo201 cells, Exp. Cell Res. 253 (1999) 533–540. doi:10.1006/excr.1999.4720.
- [358] G. Niu, T. Ye, L. Qin, P.M. Bourbon, C. Chang, S. Zhao, Y. Li, L. Zhou, P. Cui, I. Rabinovitz, A.M. Mercurio, D. Zhao, H. Zeng, Orphan nuclear receptor TR3/Nur77 improves wound healing by upregulating the expression of integrin β4, FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 29 (2015) 131–140. doi:10.1096/fj.14-257550.
- [359] X. Shen, M. Falzon, PTH-related protein upregulates integrin alpha6beta4 expression and activates Akt in breast cancer cells, Exp. Cell Res. 312 (2006) 3822–3834. doi:10.1016/j.yexcr.2006.08.011.
- [360] X. Shen, M. Falzon, PTH-related protein modulates PC3 prostate cancer cell adhesion and integrin subunit profile, Mol. Cell. Endocrinol. 199 (2003) 165–177.
- [361] W. Xuan, Y.-J. Li, G. Liu, Y. Ben-David, M.C. Archer, Interleukin-24 induces expression of beta4 integrin but suppresses anchorage-independent growth of rat mammary tumor cells by a mechanism that is independent of beta4, Mol. Cancer Res. MCR. 7 (2009) 433–442. doi:10.1158/1541-7786.MCR-08-0252.
- [362] S.-O. Yoon, S. Shin, A.M. Mercurio, Ras stimulation of E2F activity and a consequent E2F regulation of integrin alpha6beta4 promote the invasion of breast carcinoma cells, Cancer Res. 66 (2006) 6288–6295. doi:10.1158/0008-5472.CAN-06-0826.
- [363] K.M. Draheim, H.-B. Chen, Q. Tao, N. Moore, M. Roche, S. Lyle, ARRDC3 suppresses breast cancer progression by negatively regulating integrin beta4, Oncogene. 29 (2010) 5032–5047. doi:10.1038/ onc.2010.250.
- [364] J.M. Drake, J.M. Barnes, J.M. Madsen, F.E. Domann, C.S. Stipp, M.D. Henry, ZEB1 coordinately regulates laminin-332 and {beta}4 integrin expression altering the invasive phenotype of prostate cancer cells, J. Biol. Chem. 285 (2010) 33940–33948. doi:10.1074/jbc.M110.136044.

- [365] C. Sharma, I. Rabinovitz, M.E. Hemler, Palmitoylation by DHHC3 is critical for the function, expression, and stability of integrin $\alpha6\beta4$, Cell. Mol. Life Sci. CMLS. 69 (2012) 2233–2244. doi:10.1007/s00018-012-0924-6.
- [366] A. Ferraro, C.K. Kontos, T. Boni, I. Bantounas, D. Siakouli, V. Kosmidou, M. Vlassi, Y. Spyridakis, I. Tsipras, G. Zografos, A. Pintzas, Epigenetic regulation of miR-21 in colorectal cancer: ITGB4 as a novel miR-21 target and a three-gene network (miR-21-ITGB4-PDCD4) as predictor of metastatic tumor potential, Epigenetics. 9 (2014) 129–141. doi:10.4161/epi.26842.
- [367] P. Dentelli, M. Traversa, A. Rosso, G. Togliatto, C. Olgasi, C. Marchiò, P. Provero, A. Lembo, G. Bon, L. Annaratone, A. Sapino, R. Falcioni, M.F. Brizzi, miR-221/222 control luminal breast cancer tumor progression by regulating different targets, Cell Cycle Georget. Tex. 13 (2014) 1811–1826. doi:10.4161/cc.28758.
- [368] P. Gandellini, V. Profumo, A. Casamichele, N. Fenderico, S. Borrelli, G. Petrovich, G. Santilli, M. Callari, M. Colecchia, S. Pozzi, M. De Cesare, M. Folini, R. Valdagni, R. Mantovani, N. Zaffaroni, miR-205 regulates basement membrane deposition in human prostate: implications for cancer development, Cell Death Differ. 19 (2012) 1750–1760. doi:10.1038/cdd.2012.56.
- [369] A. Stallmach, B. von Lampe, H. Matthes, G. Bornhöft, E.O. Riecken, Diminished expression of integrin adhesion molecules on human colonic epithelial cells during the benign to malign tumour transformation, Gut. 33 (1992) 342–346.
- [370] I. Sordat, F.T. Bosman, G. Dorta, P. Rousselle, D. Aberdam, A.L. Blum, B. Sordat, Differential expression of laminin-5 subunits and integrin receptors in human colorectal neoplasia, J. Pathol. 185 (1998) 44–52. doi:10.1002/(SICI)1096-9896(199805)185:1<44::AID-PATH46>3.0.CO;2-A.
- [371] A.B. Dydensborg, I.C. Teller, J.-F. Groulx, N. Basora, F. Paré, E. Herring, R. Gauthier, D. Jean, J.-F. Beaulieu, Integrin alpha6Bbeta4 inhibits colon cancer cell proliferation and c-Myc activity, BMC Cancer. 9 (2009) 223. doi:10.1186/1471-2407-9-223.
- [372] T. Tennenbaum, A.J. Belanger, A.B. Glick, R. Tamura, V. Quaranta, S.H. Yuspa, A splice variant of alpha 6 integrin is associated with malignant conversion in mouse skin tumorigenesis, Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7041–7045.
- [373] K. Friedrichs, P. Ruiz, F. Franke, I. Gille, H.J. Terpe, B.A. Imhof, High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival, Cancer Res. 55 (1995) 901–906
- [374] H.L. Goel, T. Gritsko, B. Pursell, C. Chang, L.D. Shultz, D.L. Greiner, J.H. Norum, R. Toftgard, L.M. Shaw, A.M. Mercurio, Regulated Splicing of the α6 Integrin Cytoplasmic Domain Determines the Fate of Breast Cancer Stem Cells, Cell Rep. 7 (2014) 747–761. doi:10.1016/j.celrep.2014.03.059.
- [375] C. Chang, H.L. Goel, H. Gao, B. Pursell, L.D. Shultz, D.L. Greiner, S. Ingerpuu, M. Patarroyo, S. Cao, E. Lim, J. Mao, K.K. McKee, P.D. Yurchenco, A.M. Mercurio, A laminin 511 matrix is regulated by TAZ and functions as the ligand for the α6Bβ1 integrin to sustain breast cancer stem cells, Genes Dev. 29 (2015) 1–6. doi:10.1101/gad.253682.114.
- [376] M.E. Hemler, C. Crouse, A. Sonnenberg, Association of the VLA alpha 6 subunit with a novel protein. A possible alternative to the common VLA beta 1 subunit on certain cell lines, J. Biol. Chem. 264 (1989) 6529–6535.
- [377] X. Deng, Q. Li, J. Hoff, M. Novak, H. Yang, H. Jin, S.F. Erfani, C. Sharma, P. Zhou, I. Rabinovitz, A. Sonnenberg, Y. Yi, P. Zhou, C.S. Stipp, D.M. Kaetzel, M.E. Hemler, X.H. Yang, Integrin-associated CD151 drives ErbB2-evoked mammary tumor onset and metastasis, Neoplasia N. Y. N. 14 (2012) 678–689.
- [378] L.M. Sterk, C.A. Geuijen, L.C. Oomen, J. Calafat, H. Janssen, A. Sonnenberg, The tetraspan molecule CD151, a novel constituent of hemidesmosomes, associates with the integrin alpha6beta4 and may regulate the spatial organization of hemidesmosomes, J. Cell Biol. 149 (2000) 969–982.
- [379] M. Franco, C. Muratori, S. Corso, E. Tenaglia, A. Bertotti, L. Capparuccia, L. Trusolino, P.M. Comoglio, L. Tamagnone, The tetraspanin CD151 is required for Met-dependent signaling and tumor cell growth, J. Biol. Chem. 285 (2010) 38756–38764. doi:10.1074/jbc.M110.145417.

- [380] Q. Li, X.H. Yang, F. Xu, C. Sharma, H.-X. Wang, K. Knoblich, I. Rabinovitz, S.R. Granter, M.E. Hemler, Tetraspanin CD151 plays a key role in skin squamous cell carcinoma, Oncogene. 32 (2013) 1772– 1783. doi:10.1038/onc.2012.205.
- [381] K. Wilhelmsen, S.H.M. Litjens, I. Kuikman, C. Margadant, J. van Rheenen, A. Sonnenberg, Serine phosphorylation of the integrin beta4 subunit is necessary for epidermal growth factor receptor induced hemidesmosome disruption, Mol. Biol. Cell. 18 (2007) 3512–3522. doi:10.1091/mbc.E07-04-0306.
- [382] M. Herlevsen, D.-S. Schmidt, K. Miyazaki, M. Zöller, The association of the tetraspanin D6.1A with the alpha6beta4 integrin supports cell motility and liver metastasis formation, J. Cell Sci. 116 (2003) 4373–4390. doi:10.1242/jcs.00760.
- [383] B. Baudoux, D. Castanares-Zapatero, M. Leclercq-Smekens, N. Berna, Y. Poumay, The tetraspanin CD9 associates with the integrin alpha6beta4 in cultured human epidermal keratinocytes and is involved in cell motility. Eur. J. Cell Biol. 79 (2000) 41–51.
- [384] S. Huang, C.S. Chen, D.E. Ingber, Control of Cyclin D1, p27Kip1, and Cell Cycle Progression in Human Capillary Endothelial Cells by Cell Shape and Cytoskeletal Tension, Mol. Biol. Cell. 9 (1998) 3179–3193.
- [385] A.E. Aplin, S.A. Stewart, R.K. Assoian, R.L. Juliano, Integrin-Mediated Adhesion Regulates ERK Nuclear Translocation and Phosphorylation of Elk-1, J. Cell Biol. 153 (2001) 273–282.
- [386] A.E. Aplin, B.P. Hogan, J. Tomeu, R.L. Juliano, Cell adhesion differentially regulates the nucleocytoplasmic distribution of active MAP kinases, J. Cell Sci. 115 (2002) 2781–2790.
- [387] U. Dutta, L.M. Shaw, A key tyrosine (Y1494) in the beta4 integrin regulates multiple signaling pathways important for tumor development and progression, Cancer Res. 68 (2008) 8779–8787. doi:10.1158/0008-5472.CAN-08-2125.
- [388] N. Alonso-García, I. García-Rubio, J.A. Manso, R.M. Buey, H. Urien, A. Sonnenberg, G. Jeschke, J.M. de Pereda, Combination of X-ray crystallography, SAXS and DEER to obtain the structure of the FnIII-3,4 domains of integrin α6β4, Acta Crystallogr. D Biol. Crystallogr. 71 (2015) 969–985. doi:10.1107/S1399004715002485.